<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Physiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Physiol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Physiology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29459830</article-id>
<article-id pub-id-type="pmc">5807419</article-id>
<article-id pub-id-type="doi">10.3389/fphys.2018.00044</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Coenzyme Q<sub>10</sub> Supplementation in Aging and Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hernández-Camacho</surname>
<given-names>Juan D.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bernier</surname>
<given-names>Michel</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>López-Lluch</surname>
<given-names>Guillermo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/289520/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Navas</surname>
<given-names>Plácido</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/52779/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Centro Andaluz de Biología del Desarrollo and CIBERER, Instituto de Salud Carlos III, Universidad Pablo de Olavide-CSIC-JA</institution>, <addr-line>Sevilla</addr-line>, <country>Spain</country></aff>
<aff id="aff2"><sup>2</sup><institution>Translational Gerontology Branch, National Institute on Aging, National Institutes of Health</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Paolo Bernardi, Università degli Studi di Padova, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Amadou K. S. Camara, Medical College of Wisconsin, United States; Uwe Schlattner, Université Grenoble Alpes, France</p>
</fn>
<corresp id="fn001">*Correspondence: Plácido Navas <email xlink:type="simple">pnavas@upo.es</email></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Mitochondrial Research, a section of the journal Frontiers in Physiology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>44</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Hernández-Camacho, Bernier, López-Lluch and Navas.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Hernández-Camacho, Bernier, López-Lluch and Navas</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Coenzyme Q (CoQ) is an essential component of the mitochondrial electron transport chain and an antioxidant in plasma membranes and lipoproteins. It is endogenously produced in all cells by a highly regulated pathway that involves a mitochondrial multiprotein complex. Defects in either the structural and/or regulatory components of CoQ complex or in non-CoQ biosynthetic mitochondrial proteins can result in a decrease in CoQ concentration and/or an increase in oxidative stress. Besides CoQ<sub>10</sub> deficiency syndrome and aging, there are chronic diseases in which lower levels of CoQ<sub>10</sub> are detected in tissues and organs providing the hypothesis that CoQ<sub>10</sub> supplementation could alleviate aging symptoms and/or retard the onset of these diseases. Here, we review the current knowledge of CoQ<sub>10</sub> biosynthesis and primary CoQ<sub>10</sub> deficiency syndrome, and have collected published results from clinical trials based on CoQ<sub>10</sub> supplementation. There is evidence that supplementation positively affects mitochondrial deficiency syndrome and the symptoms of aging based mainly on improvements in bioenergetics. Cardiovascular disease and inflammation are alleviated by the antioxidant effect of CoQ<sub>10</sub>. There is a need for further studies and clinical trials involving a greater number of participants undergoing longer treatments in order to assess the benefits of CoQ<sub>10</sub> treatment in metabolic syndrome and diabetes, neurodegenerative disorders, kidney diseases, and human fertility.</p>
</abstract>
<kwd-group>
<kwd>Coenzyme Q</kwd>
<kwd>aging</kwd>
<kwd>disease</kwd>
<kwd>mitochondria</kwd>
<kwd>antioxidant</kwd>
<kwd>CoQ deficiency</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="126"></ref-count>
<page-count count="11"></page-count>
<word-count count="8983"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Coenzyme Q (CoQ, ubiquinone) is a unique lipid-soluble antioxidant that is produced <italic>de novo</italic> in animals (Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>). It is composed of a benzoquinone ring and a polyisoprenoid tail containing between 6 and 10 subunits that are species-specific and confers stability to the molecule inside the phospholipid bilayer. The isoprene chain in <italic>Saccharomyces cerevisiae</italic> contains six subunits (CoQ<sub>6</sub>), seven subunits are present in <italic>Crucianella maritima</italic> (CoQ<sub>7</sub>), eight in <italic>E. coli</italic> (CoQ<sub>8</sub>), nine and 10 in mice (CoQ<sub>9</sub> and CoQ<sub>10</sub>), and 10 in humans (CoQ<sub>10</sub>).</p>
<p>CoQ is a central component in the mitochondrial electron transport chain (ETC) located in the inner mitochondrial membrane where it transports electrons from complexes I and II to complex III to provide energy for proton translocation to the intermembrane space (López-Lluch et al., <xref ref-type="bibr" rid="B73">2010</xref>). CoQ is also a structural component in complexes I and III and is essential in the stabilization of complex III in yeast (Santos-Ocana et al., <xref ref-type="bibr" rid="B101">2002</xref>; Tocilescu et al., <xref ref-type="bibr" rid="B115">2010</xref>). The ETC complexes are assembled into respiratory supercomplexes in order to function efficiently and prevent electron leakage to oxygen that ultimately results in the production of reactive oxygen species (ROS) (Genova and Lenaz, <xref ref-type="bibr" rid="B44">2014</xref>; Guo et al., <xref ref-type="bibr" rid="B50">2017</xref>; Milenkovic et al., <xref ref-type="bibr" rid="B80">2017</xref>). Mitochondrial CoQ may be associated in discrete pools dedicated to either NADH-coupled or FADH<sub>2</sub>-coupled electron transport (Lapuente-Brun et al., <xref ref-type="bibr" rid="B66">2013</xref>). Complex I stability is determined by CoQ redox state (Guaras et al., <xref ref-type="bibr" rid="B49">2016</xref>) and the reduced form of CoQ (CoQH<sub>2</sub>) directs complex I-specific ROS production to extend lifespan in <italic>Drosophila</italic> (Scialo et al., <xref ref-type="bibr" rid="B105">2016</xref>). Mitochondrial activities such as the dihydroorotate dehydrogenase, β-oxidation of fatty acids, and mitochondrial glycerol-3-phosphate dehydrogenase contribute also to the increase in CoQH<sub>2</sub> levels (Alcazar-Fabra et al., <xref ref-type="bibr" rid="B3">2016</xref>) (Figure <xref ref-type="fig" rid="F1">1A</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>The multiple functions of CoQ<sub>10</sub>. <bold>(A)</bold> Mitochondria. (1) The main function of CoQ<sub>10</sub> in mitochondria is to transfer electrons to complex III (CIII). By transferring two electrons to CIII, the reduced form of CoQ<sub>10</sub> (ubiquinol) is oxidized to ubiquinone. The pool of ubiquinol can be restored by accepting electrons either from members of the electron transport chain (CI and CII), glycerol-3-phosphate dehydrogenase (GPDH) and dihydroorotate dehydrogenase (DHODH) that use cytosolic electron donors, or from acyl-CoA dehydrogenases (ACADs); (2) CoQ<sub>10</sub> is also a structural component of both CI and CIII and is associated with respiratory supercomplexes, especially the depicted supercomplex I+III+IV; (3) CoQ<sub>10</sub> is an obligatory factor in proton transport by uncoupling proteins (UCPs) with concomitant regulation of mitochondrial activity (López-Lluch et al., <xref ref-type="bibr" rid="B73">2010</xref>). <bold>(B)</bold> Cell membrane activities of CoQ<sub>10</sub>. Present in nearly all cellular membranes, CoQ<sub>10</sub> offers antioxidant protection, in part, by maintaining the reduced state of α-tocopherol (α-TOC) and ascorbic acid (ASC). Furthermore, CoQ<sub>10</sub> also regulates apoptosis by preventing lipid peroxidation. Other functions of CoQ<sub>10</sub> in cell membrane include metabolic regulation, cell signaling, and cell growth through local regulation of cytosolic redox intermediates such as NAD(P)H (López-Lluch et al., <xref ref-type="bibr" rid="B73">2010</xref>).</p>
</caption>
<graphic xlink:href="fphys-09-00044-g0001"></graphic>
</fig>
<p>CoQ provides antioxidant protection to cell membranes and plasma lipoproteins (López-Lluch et al., <xref ref-type="bibr" rid="B73">2010</xref>). By lowering lipid peroxidation of low-density lipoprotein <bold>(</bold>LDL) particles that contributes to atherosclerosis (Thomas et al., <xref ref-type="bibr" rid="B110">1997</xref>), CoQ treatment confers health benefits against cardiovascular diseases (Mortensen et al., <xref ref-type="bibr" rid="B86">2014</xref>; Alehagen et al., <xref ref-type="bibr" rid="B5">2016</xref>). The anti-oxidant function of CoQ is especially important in the plasma membrane by reducing vitamins C and E, and in preventing ceramide-mediated apoptosis (Navas et al., <xref ref-type="bibr" rid="B87">2007</xref>), an important regulator of lifespan in the context of normal aging (De Cabo et al., <xref ref-type="bibr" rid="B28">2004</xref>; López-Lluch et al., <xref ref-type="bibr" rid="B72">2005</xref>; Martin-Montalvo et al., <xref ref-type="bibr" rid="B77">2016</xref>) (Figure <xref ref-type="fig" rid="F1">1B</xref>). It has been proposed that NAD(P)H:quinone oxidoreductase 1 (NQO1) acts as a redox-sensitive switch to regulate the response of cells to changes in the redox environment (Ross and Siegel, <xref ref-type="bibr" rid="B94">2017</xref>). The pharmacokinetics variability of the different compositions of CoQ<sub>10</sub> may result in fairly different plasma concentration-time profiles after CoQ<sub>10</sub> administration (Weis et al., <xref ref-type="bibr" rid="B120">1994</xref>; Molyneux et al., <xref ref-type="bibr" rid="B82">2004</xref>). Indeed, the major amount of orally supplemented CoQ<sub>10</sub> is eliminated via feces, with only a fraction of ingested CoQ<sub>10</sub> reaching the blood and ultimately the various tissues and organs (Bentinger et al., <xref ref-type="bibr" rid="B17">2003</xref>).</p>
<p>For these reasons, CoQ appears suitable for use in the treatment of different diseases. Here, we present recent advances in CoQ<sub>10</sub> treatment of human diseases and the slowing down of the aging process, and highlight new strategies aimed at delaying the progression of chronic diseases by CoQ<sub>10</sub> supplementation.</p>
</sec>
<sec id="s2">
<title>CoQ<sub>10</sub> biosynthesis pathway</title>
<p>CoQ<sub>10</sub> biosynthesis pathway is initiated in the cytosol where the isoprene tail is made from the conversion of mevalonate, a key intermediate involved in the synthesis of cholesterol and dolichol and protein prenylation adducts (Trevisson et al., <xref ref-type="bibr" rid="B116">2011</xref>). The end of the isoprene tail is formed by a cytosolic heterotetrameric protein complex encoded by <italic>PDSS1</italic> and <italic>PDSS2</italic> genes (<italic>COQ1</italic>) (Kawamukai, <xref ref-type="bibr" rid="B63">2015</xref>). The quinone ring unit is also produced in the cytosol from tyrosine or phenylalanine and attached to the isoprene tail inside mitochondria through the activity of <italic>COQ2</italic>-encoded polyprenyl transferase (Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Acosta et al., <xref ref-type="bibr" rid="B2">2016</xref>). The benzoquinone ring is then modified in the inner mitochondrial membrane and this process involves at least 12 nuclear-encoded proteins (<italic>COQ</italic>) (Bentinger et al., <xref ref-type="bibr" rid="B18">2010</xref>), which are required for the formation of a multiprotein complex known as “synthome” (He et al., <xref ref-type="bibr" rid="B56">2014</xref>; Alcazar-Fabra et al., <xref ref-type="bibr" rid="B3">2016</xref>; Floyd et al., <xref ref-type="bibr" rid="B40">2016</xref>). The assembly and stabilization of the synthome is far from being understood as it may encompass yet to be discovered new interacting protein partners (Allan et al., <xref ref-type="bibr" rid="B7">2015</xref>; Morgenstern et al., <xref ref-type="bibr" rid="B85">2017</xref>). CoQ biosynthesis pathway is tightly regulated both at the transcriptional and translational levels (Turunen et al., <xref ref-type="bibr" rid="B118">2000</xref>; Brea-Calvo et al., <xref ref-type="bibr" rid="B23">2009</xref>; Cascajo et al., <xref ref-type="bibr" rid="B26">2016</xref>) and by phosphorylation of some of the complex components (Martin-Montalvo et al., <xref ref-type="bibr" rid="B75">2011</xref>, <xref ref-type="bibr" rid="B76">2013</xref>; Guo et al., <xref ref-type="bibr" rid="B50">2017</xref>; He et al., <xref ref-type="bibr" rid="B55">2017</xref>).</p>
</sec>
<sec id="s3">
<title>CoQ<sub>10</sub> deficiency syndrome</title>
<p>CoQ<sub>10</sub> deficiencies are based on decreased CoQ<sub>10</sub> levels and can be measured in skeletal muscle and/or skin fibroblast from patients suffering these rare (frequency less than 1:100000) inherited clinically and genetically heterogeneous diseases that impair oxidative phosphorylation and other mitochondrial functions (Desbats et al., <xref ref-type="bibr" rid="B34">2015b</xref>; Acosta et al., <xref ref-type="bibr" rid="B2">2016</xref>; Gorman et al., <xref ref-type="bibr" rid="B47">2016</xref>; Rodriguez-Aguilera et al., <xref ref-type="bibr" rid="B93">2017</xref>). CoQ<sub>10</sub> deficiency can be caused by mutations in <italic>COQ</italic> genes that encode proteins of the CoQ biosynthesis pathway (primary deficiency) or as a secondary deficiency caused by defects in other mitochondrial functions that are indirectly involved in the biosynthesis of CoQ<sub>10</sub> (Doimo et al., <xref ref-type="bibr" rid="B35">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>; Gorman et al., <xref ref-type="bibr" rid="B47">2016</xref>; Yubero et al., <xref ref-type="bibr" rid="B123">2016</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref>).</p>
<p>Primary CoQ<sub>10</sub> deficiency is characterized by highly heterogeneous clinical signs, with the severity and symptoms varying greatly as is the age of onset, which can be from birth to the seventh decade, and beyond (Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref>). Current clinical manifestations that may indicate primary CoQ<sub>10</sub> deficiency are: (1) steroid-resistant nephrotic syndrome without mutations in <italic>NPHS1</italic> and/or <italic>NPHS2</italic> genes particularly when associated with deafness, retinopathy, and other neurological defects; (2) mitochondrial encephalopathy including hypotonia, strokes, cerebellar ataxia, spasticity, peripheral neuropathy, and intellectual disability. These patients may also be presenting symptoms of myopathy, retinopathy, optic atrophy, sensorineural hearing loss, and hypertrophic cardiomyopathy; (3) unexplained ataxia particularly when family history suggests a recessive autosomal heritage; and (4) exercise intolerance appearing from 6 to 33 years of age, with muscular weakness and high serum creatine kinase.</p>
<p>Primary CoQ<sub>10</sub> deficiencies are conditions where pathogenic mutations have occurred in genes involved in the biosynthesis of CoQ<sub>10</sub> (Table <xref ref-type="table" rid="T1">1</xref>). Mutations in <italic>PDSS2, COQ6</italic>, and <italic>ADCK4/COQ8B</italic> affect mainly the kidney by inducing steroid-resistant nephrotic syndrome while <italic>COQ2</italic> mutations induce multisystem disorders whose severity correlates with the mutated genotype (Desbats et al., <xref ref-type="bibr" rid="B33">2016</xref>). Individuals affected by pathogenic mutations in the deduced amino acid sequence of <italic>COQ4, COQ7, COQ9</italic>, and/or <italic>PDSS1</italic> develop encephalopathy and those affected by mutations in <italic>ADCK3/COQ8A</italic> develop mainly cerebellar disorders.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Clinical phenotypes caused by mutations in CoQ synthome and the effect of CoQ<sub>10</sub> therapy in humans.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>N° of patients</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Age of onset</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Clinical phenotype</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Effect of CoQ therapy</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PDSS1 (COQ1)</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="left" colspan="1" rowspan="1" valign="top">1−2 years</td>
<td align="left" colspan="1" rowspan="1" valign="top">Encephalopathy, Peripheral neuropathy, Optic atrophy, Heart valvulopathy, Mild lactic acidosis, Overweight, Deafness, Moderate pulmonary artery hypertension, Mild mental retardation</td>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
<td align="left" colspan="1" rowspan="1" valign="top">Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PDSS2 (COQ1)</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">~3 months</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nephrotic syndrome, Leigh syndrome, Ataxia, Deafness, Retinopathy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>,<xref ref-type="bibr" rid="B34">b</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>COQ2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">17</td>
<td align="left" colspan="1" rowspan="1" valign="top">Birth, 3 weeks,~1 year, 18 month, Adolescence</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nephrotic syndrome, Encephalomyopathy, Hypertrophic cardiomyopathy, MELAS-like syndrome, Seizures, Retinopathy, Lactic acidosis, Deafness, Adult onset multisystem atrophy, Cerebellar atrophy, Myoclonus, Optic atrophy, Myopathy edema</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Jakobs et al., <xref ref-type="bibr" rid="B60">2013</xref>; Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>,<xref ref-type="bibr" rid="B34">b</xref>; Gigante et al., <xref ref-type="bibr" rid="B45">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>COQ4</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Birth</td>
<td align="left" colspan="1" rowspan="1" valign="top">Encephalomyopathy, Weakness, Hypotonia, Intellectual disability, Seizures, Heart failure, Myopathy, Hypertrophic cardiomyopathy, Myopathy, Dysmorphic features</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Salviati et al., <xref ref-type="bibr" rid="B100">2012</xref>, <xref ref-type="bibr" rid="B99">2017</xref>; Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>; Sondheimer et al., <xref ref-type="bibr" rid="B108">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>COQ6</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">13</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.2–6 years</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nephrotic syndrome, Deafness, Encephalopathy, Seizures, Ataxia, Growth retardation, Facial dysmorphism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Heeringa et al., <xref ref-type="bibr" rid="B57">2011</xref>; Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>COQ7</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Birth</td>
<td align="left" colspan="1" rowspan="1" valign="top">Encephalopathy, Intellectual disability, Peripheral neuropathy, Muscle weakness</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Freyer et al., <xref ref-type="bibr" rid="B42">2015</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ADCK3 (COQ8A)</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">23</td>
<td align="left" colspan="1" rowspan="1" valign="top">18 months, 1–2, 3–11, 15–18, 27 years</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerebellar ataxia, Encephalopathy, Seizures, Dystonia, Spasticity, Migraine, Exercise intolerance, Myoclonus, Intellectual disability, Hypotonia, Muscle fragility, Feeding difficulties, Walking difficulty</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>; Barca et al., <xref ref-type="bibr" rid="B12">2016</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ADCK4 (COQ8B)</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">15</td>
<td align="left" colspan="1" rowspan="1" valign="top">&lt;1, 3–14, 16–21 years</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mental retardation, Nephrotic syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ashraf et al., <xref ref-type="bibr" rid="B11">2013</xref>; Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>COQ9</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Birth</td>
<td align="left" colspan="1" rowspan="1" valign="top">Encephalomyopathy, Renal tubulopathy, Cardiac hypertrophy, Seizures, Cerebellar atrophy, Myopathy</td>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
<td align="left" colspan="1" rowspan="1" valign="top">Laredj et al., <xref ref-type="bibr" rid="B67">2014</xref>; Desbats et al., <xref ref-type="bibr" rid="B32">2015a</xref>; Salviati et al., <xref ref-type="bibr" rid="B99">2017</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Abnormally low CoQ<sub>10</sub> levels can be associated with mitochondrial pathologies caused by mutations in genes encoding components of the oxidative phosphorylation chain or of other cellular functions not directly associated with mitochondrial function (Yubero et al., <xref ref-type="bibr" rid="B123">2016</xref>). Known as secondary CoQ<sub>10</sub> deficiencies, these disorders could represent an adaptive mechanism to bioenergetic requirements. For example, secondary CoQ<sub>10</sub> deficiency can appear in some patients with defects in glucose transport caused by <italic>GLUT1</italic> mutations (Yubero et al., <xref ref-type="bibr" rid="B124">2014</xref>). A group of patients with very severe neuropathies showed impaired CoQ<sub>10</sub> synthesis, indicating the importance of CoQ<sub>10</sub> homeostasis in human health (Asencio et al., <xref ref-type="bibr" rid="B10">2016</xref>).</p>
<p>In individuals with primary CoQ<sub>10</sub> deficiency, early treatment with high-dose oral CoQ<sub>10</sub> supplementation improves the pathological phenotype, limits the progression of encephalopathy, and helps recover kidney damage (Montini et al., <xref ref-type="bibr" rid="B83">2008</xref>). Onset of renal symptoms in <italic>PDSS2</italic>-deficient mice can be prevented with CoQ<sub>10</sub> supplementation (Saiki et al., <xref ref-type="bibr" rid="B98">2008</xref>). The European Medicine Agency (EMA) has recently approved ubiquinol—the reduced form of CoQ<sub>10</sub> (CoQ<sub>10</sub>H<sub>2</sub>)—as an orphan drug for the treatment of primary CoQ<sub>10</sub> deficiency (<ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/health/documents/community-register/html/o1765.htm">http://ec.europa.eu/health/documents/community-register/html/o1765.htm</ext-link>). However, patients suffering from secondary CoQ<sub>10</sub> deficiency may fail to respond to CoQ<sub>10</sub> supplementation (Pineda et al., <xref ref-type="bibr" rid="B90">2010</xref>).</p>
</sec>
<sec id="s4">
<title>CoQ<sub>10</sub> and aging</title>
<p>A significant reduction in the rate of CoQ biosynthesis has been proposed to occur during the aging process and aging-associated diseases (Beyer et al., <xref ref-type="bibr" rid="B19">1985</xref>; Kalen et al., <xref ref-type="bibr" rid="B62">1989</xref>; Battino et al., <xref ref-type="bibr" rid="B13">1995</xref>; Turunen et al., <xref ref-type="bibr" rid="B117">1999</xref>). However, there are discrepancies about the relationship between the levels of CoQ and the progression of aging.</p>
<p>Mice lacking one of the alleles of the <italic>COQ7</italic> gene (<italic>mCOQ7/mCLK1 gene</italic>) show extended longevity even though their CoQ levels are the same as wild-type mice, suggesting that a factor other than CoQ <italic>per se</italic> may be responsible for lifespan extension in these animals (Lapointe and Hekimi, <xref ref-type="bibr" rid="B65">2008</xref>). However, other <italic>in vivo</italic> studies have reported a direct association between longevity and mitochondrial levels of CoQ in the <italic>Samp1</italic> model of senescence-accelerated mice (Tian et al., <xref ref-type="bibr" rid="B112">2014</xref>). Supplementation with ubiquinol has been shown to activate mechanisms controlling mitochondrial biogenesis (Schmelzer et al., <xref ref-type="bibr" rid="B103">2010</xref>) and delay senescence (Tian et al., <xref ref-type="bibr" rid="B112">2014</xref>).</p>
<p>The concentrations of CoQ<sub>10</sub> in the plasma of elderly people are positively correlated with levels of physical activity and cholesterol concentrations (Del Pozo-Cruz et al., <xref ref-type="bibr" rid="B30">2014a</xref>,<xref ref-type="bibr" rid="B31">b</xref>), as well as with lower lipid oxidative damage. The antioxidant protection conferred by CoQ<sub>10</sub> is associated with skeletal muscle performance during aging as evidenced by the fact that a high CoQ<sub>10</sub>H<sub>2</sub>/CoQ<sub>10</sub> ratio is accompanied by an increase in muscle strength (Fischer et al., <xref ref-type="bibr" rid="B38">2016</xref>). Conversely, a low CoQ<sub>10</sub>H<sub>2</sub>/CoQ<sub>10</sub> ratio could be predictor of sarcopenia in humans. Older individuals given a combination of selenium and CoQ<sub>10</sub> over a 4-year period reported an improvement in vitality, physical performance, and quality of life (Johansson et al., <xref ref-type="bibr" rid="B61">2015</xref>). Furthermore, CoQ<sub>10</sub> supplementation confers health benefits in elderly people by preventing chronic oxidative stress associated with cardiovascular and neurodegenerative diseases (Gonzalez-Guardia et al., <xref ref-type="bibr" rid="B46">2015</xref>). Despite these evidences, more reliable clinical trials focusing on the elderly are needed before considering CoQ<sub>10</sub> as an effective anti-aging therapy (Varela-Lopez et al., <xref ref-type="bibr" rid="B119">2016</xref>).</p>
</sec>
<sec id="s5">
<title>CoQ<sub>10</sub> supplementation in the treatment of human diseases</title>
<p>CoQ<sub>10</sub> has been used in the treatment of a number of human pathologies and disorders. Clinical trials, systematic reviews, and meta-analyses have examined the safety and efficacy of CoQ<sub>10</sub> in treating human diseases. With regards to safety, the highest dose for CoQ<sub>10</sub> supplementation is 1200 mg daily according to well-designed randomized, controlled human trials, although doses as high as 3000 mg/day have been used in shorter clinical trials (Hathcock and Shao, <xref ref-type="bibr" rid="B54">2006</xref>). CoQ is generally safe and well-tolerated in treating patients suffering from early-stage Huntington disease with 2400 mg/day of CoQ<sub>10</sub> (McGarry et al., <xref ref-type="bibr" rid="B79">2017</xref>).</p>
<p>As indicated below, prudence is needed when interpreting the results of several clinical trials. A combination of factors including the small number of trials, substantial differences that exist in the experimental designs, dose and duration of treatment, the number of patients enrolled, and the relative short follow-up periods contribute to apparent inconsistencies in the published data. Despite these limitations, CoQ<sub>10</sub> can be considered as an important coadjuvant in the treatment of different diseases, especially in chronic conditions affecting the elderly.</p>
<sec>
<title>Cardiovascular disease</title>
<p>The number of deaths attributed to heart failure is increasing worldwide and has become a global health issue. Heart failure is accompanied by increased ROS formation, which can be attenuated with antioxidants. A systematic review has recently examined the efficacy of CoQ<sub>10</sub> supplementation in the prevention of cardiovascular disease (CVD) without lifestyle intervention (Flowers et al., <xref ref-type="bibr" rid="B39">2014</xref>). These authors interpreted the results to indicate a significant reduction in systolic blood pressure without improvements in other CVD risk factors, such as diastolic blood pressure, total cholesterol, LDL- and high-density lipoprotein (HDL)-cholesterol, and triglycerides. A second meta-analysis explored the impact of CoQ<sub>10</sub> in the prevention of complications in patients undergoing cardiac surgery, and the results showed that CoQ<sub>10</sub> therapy lowers the need of inotropic drugs and reduces the appearance of ventricular arrhythmias after surgery (de Frutos et al., <xref ref-type="bibr" rid="B29">2015</xref>).</p>
<p>Short-term daily treatment (12 weeks or less) with 100 mg CoQ<sub>10</sub> improves left ventricular ejection fraction in patients suffering from heart failure (Fotino et al., <xref ref-type="bibr" rid="B41">2013</xref>). In contrast, no effect of CoQ<sub>10</sub> was observed on left ventricular ejection fraction or exercise capacity in patients with heart failure (Madmani et al., <xref ref-type="bibr" rid="B74">2014</xref>). However, a 2-year treatment with CoQ<sub>10</sub> (300 mg/day) as adjunctive therapy in a randomized, controlled multicenter trial affecting 420 patients suffering from chronic heart failure (Q-SYMBIO trial) demonstrated an improvement in symptoms and reduction in major cardiovascular events (Mortensen et al., <xref ref-type="bibr" rid="B86">2014</xref>). A study on the effects of long-term treatment with CoQ<sub>10</sub> (200 mg/day) plus selenium (200 μg as selenized yeast) in a homogeneous Swedish healthy elderly population (<italic>n</italic> = 219) revealed a significant reduction in cardiovascular mortality not only during the 4-year treatment period, but also 10 years later, compared to those taking either a placebo (<italic>n</italic> = 222) or were without treatment (<italic>n</italic> = 227) (Alehagen et al., <xref ref-type="bibr" rid="B4">2015</xref>, <xref ref-type="bibr" rid="B5">2016</xref>).</p>
</sec>
<sec>
<title>Metabolic syndrome and diabetes</title>
<p>CoQ<sub>10</sub> has been proposed for the treatment of metabolic syndrome and type 2 diabetes by virtue of its antioxidant properties. However, current results from clinical trials cannot conclusively determine the efficacy of CoQ<sub>10</sub> because either of the missing information on the CoQ<sub>10</sub> formulation used or the low number of trials and/or patients enrolled.</p>
<p>One effect attributable to CoQ<sub>10</sub> therapy in type 2 diabetic patients (260 mg/day for 11 weeks) is its rather mild, but significant capacity to reduce fasting plasma glucose levels without changes in fasting insulin and glycated hemoglobin (HbA1c) (Moradi et al., <xref ref-type="bibr" rid="B84">2016</xref>). However, analysis of more than seven trials involving 356 participants showed that CoQ<sub>10</sub> supplementation for at least 12 weeks had no significant effects on glycemic control, lipid profile, or blood pressure in diabetic patients, but was able to reduce serum triglycerides levels (Suksomboon et al., <xref ref-type="bibr" rid="B109">2015</xref>). In a follow-up analysis of data obtained from Q-SYMBIO clinical trials (Mortensen et al., <xref ref-type="bibr" rid="B86">2014</xref>), Alehagen and colleagues were able to show that in elderly healthy participants who received selenium and CoQ<sub>10</sub> supplementation for over 4 years, an increase in insulin-like growth factor 1 (IGF-1) and postprandial insulin-like growth factor-binding protein 1 (IGFBP-1) levels, and greater age-corrected IGF-1 score based on the standard deviation of the mean value were observed compared with placebo-treated individuals (Alehagen et al., <xref ref-type="bibr" rid="B6">2017</xref>).</p>
<p>Supplementation with CoQ<sub>10</sub> has produced beneficial effects in the treatment of hypercholesterolemia and hypertriglyceridemia by initiating changes in blood lipid concentration. A combination of CoQ<sub>10</sub> with red yeast rice, berberina, policosanol, astaxanthin, and folic acid significantly decreased total cholesterol, LDL-cholesterol, triglycerides, and glucose in the blood while increasing HDL-cholesterol levels (Pirro et al., <xref ref-type="bibr" rid="B91">2016</xref>). However, the impact of CoQ<sub>10</sub> alone without the other supplements was not directly assessed. Nevertheless, there are reports to suggest that CoQ<sub>10</sub> is very effective in reducing serum triglycerides levels (Suksomboon et al., <xref ref-type="bibr" rid="B109">2015</xref>) and plasma lipoprotein(a) (Sahebkar et al., <xref ref-type="bibr" rid="B97">2016</xref>). Chronic treatment with statins is associated with myopathy (Law and Rudnicka, <xref ref-type="bibr" rid="B68">2006</xref>), a side-effect representing a broad clinical spectrum of disorders largely associated with a decrease in CoQ<sub>10</sub> levels and selenoprotein activity (Thompson et al., <xref ref-type="bibr" rid="B111">2003</xref>; Fedacko et al., <xref ref-type="bibr" rid="B37">2013</xref>). Statins impair skeletal muscle and myocardial bioenergetics (Littarru and Langsjoen, <xref ref-type="bibr" rid="B69">2007</xref>) via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, a key enzyme in the mevalonate pathway implicated in cholesterol and CoQ biosynthesis, and reduction in mitochondrial complex III activity of the electron transport chain (Schirris et al., <xref ref-type="bibr" rid="B102">2015</xref>). A total of 60 patients suffering from statin-associated myopathy were enrolled in a 3-month study to test for efficacy of CoQ<sub>10</sub> and selenium treatment. A consistent reduction in their symptoms, including muscle pain, weakness, cramps, and fatigue was observed, suggesting an attenuation of the side-effects of chronic statin treatment following CoQ<sub>10</sub> supplementation (Fedacko et al., <xref ref-type="bibr" rid="B37">2013</xref>). In a previous study, however, 44 patients suffering from statin-induced myalgia saw no improvement in their conditions after receiving CoQ<sub>10</sub> for 3 months (Young et al., <xref ref-type="bibr" rid="B122">2007</xref>). Other studies have determined that CoQ<sub>10</sub> supplementation improves endothelial dysfunction in type 2 diabetic patients treated with statins (Hamilton et al., <xref ref-type="bibr" rid="B53">2009</xref>) and can reverse the worsening of the diastolic function induced by statins (Silver et al., <xref ref-type="bibr" rid="B107">2004</xref>).</p>
<p>Because of its capacity to reduce the side-effects of statins, CoQ<sub>10</sub> has been proposed to prevent and/or slow the progression of frailty and sarcopenia in the elderly chronically treated with statins.</p>
</sec>
<sec>
<title>Kidney disease</title>
<p>Oxidative stress plays an essential role in diabetic kidney disease, and experiments performed on rats showed a promising protective effect of ubiquinol in the kidneys (Ishikawa et al., <xref ref-type="bibr" rid="B58">2011</xref>). However, a meta-analysis study examining the efficiency of antioxidants on the initiation and progression of diabetic kidney disease revealed that antioxidants, including CoQ<sub>10</sub>, did not have reliable effects against this disease (Bolignano et al., <xref ref-type="bibr" rid="B21">2017</xref>). Yet, in a recent clinical trial with 65 patients undergoing hemodialysis, supplementation with high amounts of CoQ<sub>10</sub> (1200 mg/day) lowered F2-isoprostane plasma levels indicative of a reduction in oxidative stress (Rivara et al., <xref ref-type="bibr" rid="B92">2017</xref>).</p>
</sec>
<sec>
<title>Inflammation</title>
<p>Chronic inflammation and oxidative stress are associated with many age-related diseases such as cardiovascular diseases, diabetes, cancer, and chronic kidney disease. A recent meta-analysis explored the efficacy of CoQ<sub>10</sub> on the plasma levels of C-reactive protein, interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients afflicted with pathologies in which inflammation was a common factor including cardio-cerebral vascular disease, multiple sclerosis, obesity, renal failure, rheumatoid arthritis, diabetes, and fatty liver disease (Fan et al., <xref ref-type="bibr" rid="B36">2017</xref>). Administration of CoQ<sub>10</sub> in doses ranging from 60 to 500 mg/day for a 1-week to 4-month intervention period significantly decreased production of inflammatory cytokines. The authors also surmised that CoQ<sub>10</sub> supplementation decreased pro-inflammatory cytokines and inflammatory markers in the elderly with low CoQ<sub>10</sub> levels (Fan et al., <xref ref-type="bibr" rid="B36">2017</xref>).</p>
<p>Metabolic diseases, characterized by chronic, low grade inflammation, respond well to CoQ<sub>10</sub> supplementation with significant decrease in TNF-α plasma levels without having an effect on C-reactive protein and IL-6 production (Zhai et al., <xref ref-type="bibr" rid="B126">2017</xref>). Rheumatoid arthritis patients receiving CoQ<sub>10</sub> (100 mg/day) for 2 months tended to have lower TFN-α plasma levels than placebo-treated patients (Abdollahzad et al., <xref ref-type="bibr" rid="B1">2015</xref>). Another study reported that CoQ<sub>10</sub> therapy in doses ranging from 60 to 300 mg/day caused no significant decrease in C-reactive protein while eliciting a significant reduction in IL-6 levels (Mazidi et al., <xref ref-type="bibr" rid="B78">2017</xref>). More recently, CoQ<sub>10</sub> has been found to markedly attenuate the elevated expression of inflammatory and thrombotic risk markers in monocytes of patients with antiphospholipid syndrome, thereby improving endothelial function and mitochondrial activity in these patients (Perez-Sanchez et al., <xref ref-type="bibr" rid="B89">2017</xref>).</p>
<p>A proinflammatory profile has also been associated with the progression of neurological symptoms in Down syndrome patients (Wilcock and Griffin, <xref ref-type="bibr" rid="B121">2013</xref>). These patients have low CoQ<sub>10</sub> plasma levels together with high plasma levels of proinflammatory cytokines, such as IL-6 and TNF-α (Zaki et al., <xref ref-type="bibr" rid="B125">2017</xref>). Supplementation with CoQ<sub>10</sub> confers protection against the progression of oxidative damage and mitochondrial dysfunction in Down syndrome patients (Tiano and Busciglio, <xref ref-type="bibr" rid="B113">2011</xref>; Tiano et al., <xref ref-type="bibr" rid="B114">2011</xref>).</p>
</sec>
<sec>
<title>Neurodegenerative diseases</title>
<p>Mitochondrial dysfunction has been associated with the onset and/or development of neurodegenerative diseases (Arun et al., <xref ref-type="bibr" rid="B9">2016</xref>; Bose and Beal, <xref ref-type="bibr" rid="B22">2016</xref>; Grimm et al., <xref ref-type="bibr" rid="B48">2016</xref>). Preclinical studies demonstrated that CoQ can preserve mitochondrial function and reduce the loss of dopaminergic neurons in the case of Parkinson's disease (Schulz and Beal, <xref ref-type="bibr" rid="B104">1995</xref>). Experimental studies in animal models suggest that CoQ<sub>10</sub> may protect against neuronal damage caused by ischemia, atherosclerosis, and toxic injury (Ishrat et al., <xref ref-type="bibr" rid="B59">2006</xref>). Further, a screening for oxidative stress markers in patients with Parkinson's disease reported lower levels of CoQ<sub>10</sub> and α-tocopherol and higher levels of lipoprotein oxidation in the plasma and cerebrospinal fluid compared to non-affected individuals (Buhmann et al., <xref ref-type="bibr" rid="B24">2004</xref>). Moreover, CoQ<sub>10</sub> deficiency was observed at a higher frequency in Parkinson's disease, underscoring its utility as a peripheral biomarker (Mischley et al., <xref ref-type="bibr" rid="B81">2012</xref>). For this reason, it has been suggested that CoQ<sub>10</sub> supplementation could benefit patients suffering from neurodegenerative diseases.</p>
<p>Studies in humans have shown that CoQ<sub>10</sub> is safe and well-tolerated even at high doses (1200–2400 mg/day) although its effect on reversing functional decline of mitochondria is unclear (Schulz and Beal, <xref ref-type="bibr" rid="B104">1995</xref>; McGarry et al., <xref ref-type="bibr" rid="B79">2017</xref>). Two reviews on recent clinical trials testing CoQ<sub>10</sub> supplementation reported the lack of improvement in motor functions in patients with neurodegenerative diseases, which led the authors to conclude that the use of CoQ<sub>10</sub> in these patients is unnecessary (Liu and Wang, <xref ref-type="bibr" rid="B70">2014</xref>; Negida et al., <xref ref-type="bibr" rid="B88">2016</xref>). However, other clinical trials in patients suffering from Parkinson's, Huntington's, and Friedreich's ataxia suggest that CoQ<sub>10</sub> supplementation could delay functional decline, particularly with regard to Parkinson's disease (Beal, <xref ref-type="bibr" rid="B14">2002</xref>; Shults, <xref ref-type="bibr" rid="B106">2003</xref>). Indeed, four randomized, double-blind, placebo-controlled studies comparing CoQ<sub>10</sub> treatment in 452 patients at early or mid-stage Parkinson's disease reported improvements in daily activities and other parameters (Liu et al., <xref ref-type="bibr" rid="B71">2011</xref>). In contrast, a more recent multicenter randomized, double-blind, and placebo-controlled trial with CoQ<sub>10</sub> in 609 patients with early-stage Huntington's disease did not slow the rate of patients' functional decline (McGarry et al., <xref ref-type="bibr" rid="B79">2017</xref>). There is not enough evidence to indicate that CoQ<sub>10</sub> supplementation can delay the progression of Huntington's disease, at least in its early stages.</p>
<p>Initiated in 2006, the Alzheimer's Disease Cooperative Study evaluates the safety, tolerability, and impact of different antioxidants on biomarkers in this disease. There was no improvement observed in oxidative stress or neurodegeneration markers in a randomized clinical trial in Alzheimer's Disease patients with CoQ<sub>10</sub> supplementation at a dose of 400 mg/day for 16 weeks (Galasko et al., <xref ref-type="bibr" rid="B43">2012</xref>).</p>
<p>The role of plasma membrane CoQ<sub>10</sub> in autism has been recently proposed (Crane et al., <xref ref-type="bibr" rid="B27">2014</xref>). Patients with autistic spectrum disorders (ASDs) exhibit higher proportions of mitochondrial dysfunctions than the general population (Rossignol and Frye, <xref ref-type="bibr" rid="B95">2012</xref>), as evidenced by developmental regression, seizures, and elevated serum levels of lactate or pyruvate in ASD patients. Treatment with carnitine, CoQ<sub>10</sub>, and B-vitamins confers some improvements in ASD patients (Rossignol and Frye, <xref ref-type="bibr" rid="B95">2012</xref>; Gvozdjakova et al., <xref ref-type="bibr" rid="B52">2014</xref>).</p>
<p>Alleviation of symptoms of chronic fatigue syndrome/myalgic encephalomyelitis has been reported after supplementation with a combination of NADH and CoQ<sub>10</sub> (Campagnolo et al., <xref ref-type="bibr" rid="B25">2017</xref>); however, these authors suggest that nutritional supplements in the mitigation of the symptoms of this disease are not currently justifiable.</p>
</sec>
<sec>
<title>Human fertility</title>
<p>Male infertility has been associated with oxidative stress, and CoQ<sub>10</sub> levels in seminal fluid is considered an important biomarker of healthy sperm (Gvozdjakova et al., <xref ref-type="bibr" rid="B51">2015</xref>). Administration of CoQ<sub>10</sub> improves semen parameters in the treatment of idiopathic male infertility (Arcaniolo et al., <xref ref-type="bibr" rid="B8">2014</xref>). Additionally, CoQ<sub>10</sub> supplementation (200–300 mg/day) in men with infertility improves sperm concentration, density, motility, and morphology (Safarinejad et al., <xref ref-type="bibr" rid="B96">2012</xref>; Lafuente et al., <xref ref-type="bibr" rid="B64">2013</xref>).</p>
<p>With regard to female infertility, the decrease in mitochondrial activity associated with CoQ<sub>10</sub> deficiency probably affects the granulosa cells' capacity to generate ATP (Ben-Meir et al., <xref ref-type="bibr" rid="B16">2015b</xref>). Indeed, reduction of CoQ<sub>10</sub> levels in oocyte-specific <italic>PDSS2</italic>-deficient mice results in oocyte deficits and infertility (Ben-Meir et al., <xref ref-type="bibr" rid="B15">2015a</xref>). Despite the absence of previous clinical trials that evaluate the effectiveness of CoQ<sub>10</sub> supplementation in female infertility, these studies show promising results of this natural supplement in boosting female fertility during the prime reproductive period.</p>
</sec>
</sec>
<sec id="s6">
<title>Concluding remarks</title>
<p>CoQ<sub>10</sub> deficiency can be associated with a number of human diseases and age-related chronic conditions. In some cases, an unbalanced equilibrium between CoQ<sub>10</sub> levels and/or functional ETC leads to mitochondrial dysfunction. In other cases, deficiency in CoQ<sub>10</sub> and its associated antioxidative activity can significantly increase the level of oxidative damage. It seems clear that supplementation with CoQ<sub>10</sub> improves mitochondrial function and confers antioxidant protection for organs and tissues affected by various pathophysiological conditions. The ability of CoQ<sub>10</sub> to protect against the release of proinflammatory markers provides an attractive anti-inflammatory therapeutic for the treatment of some human diseases and in aging (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Effects of CoQ<sub>10</sub> in human diseases. The positive effect of CoQ<sub>10</sub> has been already demonstrated in mitochondrial syndromes associated with CoQ<sub>10</sub> deficiency, inflammation, and cardiovascular diseases as well as in the delay of some age-related processes. Dashed lines depict other positive effects of CoQ<sub>10</sub> with regard to kidney disease, fertility, metabolic syndrome, diabetes, and neurodegenerative diseases. However, more research is needed to validate these observations.</p>
</caption>
<graphic xlink:href="fphys-09-00044-g0002"></graphic>
</fig>
<p>Following intraperitoneal administration of CoQ<sub>10</sub> in rat, only small amount of the supplement reaches the kidney, muscle, and brain. Likewise, only a fraction of the orally administered CoQ<sub>10</sub> reaches the blood while the major amount is eliminated via feces (Bentinger et al., <xref ref-type="bibr" rid="B17">2003</xref>). The absoption of CoQ<sub>10</sub> is slow and limited due to its hydrophobicity and large molecular weight and, therefore, high doses are needed to reach a number of rat tissues (e.g., muscle and brain) (Bhagavan and Chopra, <xref ref-type="bibr" rid="B20">2006</xref>) and we can only assume that this also happens in humans. The pharmacokinetics variability of the different compositions of CoQ<sub>10</sub> (Weis et al., <xref ref-type="bibr" rid="B120">1994</xref>; Molyneux et al., <xref ref-type="bibr" rid="B82">2004</xref>) may result in fairly different plasma concentration-time profiles after CoQ<sub>10</sub> administration in the treatment of various diseases and monitoring of clinical effects.</p>
<p>Systematic reviews and meta-analyses have revealed that there are few randomized clinical trials on the effect of CoQ<sub>10</sub> in combatting disease progression and improving quality of life. The results of these trials have been inconsistent likely due to varied dosages, small sample size, and short follow-up periods. More studies performed on humans in focused trials are needed in order to understand the promising effects of CoQ<sub>10</sub>.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work has been partially funded by the Spanish Ministry of Health, Instituto de Salud Carlos III (ISCIII), FIS PI14-01962, and the Andalusian Government grant BIO177 (FEDER funds of European Commission). JH-C has been awarded by CIBERER, Instituto de Salud Carlos III. This work was also supported, in part, by the Intramural Research Program of the National Institute on Aging, NIH.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdollahzad</surname><given-names>H.</given-names></name><name><surname>Aghdashi</surname><given-names>M. A.</given-names></name><name><surname>Asghari Jafarabadi</surname><given-names>M.</given-names></name><name><surname>Alipour</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Effects of coenzyme Q10 supplementation on inflammatory cytokines (TNF-alpha, IL-6) and oxidative stress in rheumatoid arthritis patients: a randomized controlled trial</article-title>. <source/>Arch. Med. Res.
<volume>46</volume>, <fpage>527</fpage>–<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1016/j.arcmed.2015.08.006</pub-id><pub-id pub-id-type="pmid">26342738</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta</surname><given-names>M. J.</given-names></name><name><surname>Vazquez Fonseca</surname><given-names>L.</given-names></name><name><surname>Desbats</surname><given-names>M. A.</given-names></name><name><surname>Cerqua</surname><given-names>C.</given-names></name><name><surname>Zordan</surname><given-names>R.</given-names></name><name><surname>Trevisson</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Coenzyme Q biosynthesis in health and disease</article-title>. <source/>Biochim. Biophys. Acta
<volume>1857</volume>, <fpage>1079</fpage>–<lpage>1085</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2016.03.036</pub-id><pub-id pub-id-type="pmid">27060254</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcazar-Fabra</surname><given-names>M.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>Brea-Calvo</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Coenzyme Q biosynthesis and its role in the respiratory chain structure</article-title>. <source/>Biochim. Biophys. Acta
<volume>1857</volume>, <fpage>1073</fpage>–<lpage>1078</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2016.03.010</pub-id><pub-id pub-id-type="pmid">26970214</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alehagen</surname><given-names>U.</given-names></name><name><surname>Aaseth</surname><given-names>J.</given-names></name><name><surname>Johansson</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Reduced cardiovascular mortality 10 years after supplementation with selenium and coenzyme Q10 for four years: follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly citizens</article-title>. <source/>PLoS ONE
<volume>10</volume>:<fpage>e0141641</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0141641</pub-id><pub-id pub-id-type="pmid">26624886</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alehagen</surname><given-names>U.</given-names></name><name><surname>Alexander</surname><given-names>J.</given-names></name><name><surname>Aaseth</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Supplementation with selenium and coenzyme Q10 reduces cardiovascular mortality in elderly with low selenium status. A secondary analysis of a randomised clinical trial</article-title>. <source/>PLoS ONE
<volume>11</volume>:<fpage>e0157541</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0157541</pub-id><pub-id pub-id-type="pmid">27367855</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alehagen</surname><given-names>U.</given-names></name><name><surname>Johansson</surname><given-names>P.</given-names></name><name><surname>Aaseth</surname><given-names>J.</given-names></name><name><surname>Alexander</surname><given-names>J.</given-names></name><name><surname>Brismar</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Increase in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 after supplementation with selenium and coenzyme Q10. A prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens</article-title>. <source/>PLoS ONE
<volume>12</volume>:<fpage>e0178614</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0178614</pub-id><pub-id pub-id-type="pmid">28609475</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>C. M.</given-names></name><name><surname>Awad</surname><given-names>A. M.</given-names></name><name><surname>Johnson</surname><given-names>J. S.</given-names></name><name><surname>Shirasaki</surname><given-names>D. I.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Blaby-Haas</surname><given-names>C. E.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Identification of Coq11, a new coenzyme Q biosynthetic protein in the CoQ-synthome in Saccharomyces cerevisiae</article-title>. <source/>J. Biol. Chem.
<volume>290</volume>, <fpage>7517</fpage>–<lpage>7534</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.633131</pub-id><pub-id pub-id-type="pmid">25631044</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcaniolo</surname><given-names>D.</given-names></name><name><surname>Favilla</surname><given-names>V.</given-names></name><name><surname>Tiscione</surname><given-names>D.</given-names></name><name><surname>Pisano</surname><given-names>F.</given-names></name><name><surname>Bozzini</surname><given-names>G.</given-names></name><name><surname>Creta</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Is there a place for nutritional supplements in the treatment of idiopathic male infertility?</article-title>
<source/>Arch. Ital. Urol. Androl.
<volume>86</volume>, <fpage>164</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.4081/aiua.2014.3.164</pub-id><pub-id pub-id-type="pmid">25308577</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arun</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Donmez</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Mitochondrial biology and neurological diseases</article-title>. <source/>Curr. Neuropharmacol.
<volume>14</volume>, <fpage>143</fpage>–<lpage>154</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X13666150703154541</pub-id><pub-id pub-id-type="pmid">26903445</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asencio</surname><given-names>C.</given-names></name><name><surname>Rodriguez-Hernandez</surname><given-names>M. A.</given-names></name><name><surname>Briones</surname><given-names>P.</given-names></name><name><surname>Montoya</surname><given-names>J.</given-names></name><name><surname>Cortes</surname><given-names>A.</given-names></name><name><surname>Emperador</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Severe encephalopathy associated to pyruvate dehydrogenase mutations and unbalanced coenzyme Q10 content</article-title>. <source/>Eur. J. Hum. Genet.
<volume>24</volume>, <fpage>367</fpage>–<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2015.112</pub-id><pub-id pub-id-type="pmid">26014431</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashraf</surname><given-names>S.</given-names></name><name><surname>Gee</surname><given-names>H. Y.</given-names></name><name><surname>Woerner</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>L. X.</given-names></name><name><surname>Vega-Warner</surname><given-names>V.</given-names></name><name><surname>Lovric</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption</article-title>. <source/>J. Clin. Invest.
<volume>123</volume>, <fpage>5179</fpage>–<lpage>5189</lpage>. <pub-id pub-id-type="doi">10.1172/JCI69000</pub-id><pub-id pub-id-type="pmid">24270420</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barca</surname><given-names>E.</given-names></name><name><surname>Musumeci</surname><given-names>O.</given-names></name><name><surname>Montagnese</surname><given-names>F.</given-names></name><name><surname>Marino</surname><given-names>S.</given-names></name><name><surname>Granata</surname><given-names>F.</given-names></name><name><surname>Nunnari</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Cerebellar ataxia and severe muscle CoQ10 deficiency in a patient with a novel mutation in ADCK3</article-title>. <source/>Clin. Genet.
<volume>90</volume>, <fpage>156</fpage>–<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1111/cge.12742</pub-id><pub-id pub-id-type="pmid">26818466</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battino</surname><given-names>M.</given-names></name><name><surname>Gorini</surname><given-names>A.</given-names></name><name><surname>Villa</surname><given-names>R. F.</given-names></name><name><surname>Genova</surname><given-names>M. L.</given-names></name><name><surname>Bovina</surname><given-names>C.</given-names></name><name><surname>Sassi</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>Coenzyme Q content in synaptic and non-synaptic mitochondria from different brain regions in the ageing rat</article-title>. <source/>Mech. Ageing Dev.
<volume>78</volume>, <fpage>173</fpage>–<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/0047-6374(94)01535-T</pub-id><pub-id pub-id-type="pmid">7596200</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2002</year>). <article-title>Coenzyme Q10 as a possible treatment for neurodegenerative diseases</article-title>. <source/>Free Radic. Res.
<volume>36</volume>, <fpage>455</fpage>–<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1080/10715760290021315</pub-id><pub-id pub-id-type="pmid">12069110</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Meir</surname><given-names>A.</given-names></name><name><surname>Burstein</surname><given-names>E.</given-names></name><name><surname>Borrego-Alvarez</surname><given-names>A.</given-names></name><name><surname>Chong</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>E.</given-names></name><name><surname>Yavorska</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2015a</year>). <article-title>Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging</article-title>. <source/>Aging Cell
<volume>14</volume>, <fpage>887</fpage>–<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1111/acel.12368</pub-id><pub-id pub-id-type="pmid">26111777</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Meir</surname><given-names>A.</given-names></name><name><surname>Yahalomi</surname><given-names>S.</given-names></name><name><surname>Moshe</surname><given-names>B.</given-names></name><name><surname>Shufaro</surname><given-names>Y.</given-names></name><name><surname>Reubinoff</surname><given-names>B.</given-names></name><name><surname>Saada</surname><given-names>A.</given-names></name></person-group> (<year>2015b</year>). <article-title>Coenzyme Q-dependent mitochondrial respiratory chain activity in granulosa cells is reduced with aging</article-title>. <source/>Fertil. Steril.
<volume>104</volume>, <fpage>724</fpage>–<lpage>727</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2015.05.023</pub-id><pub-id pub-id-type="pmid">26049051</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentinger</surname><given-names>M.</given-names></name><name><surname>Dallner</surname><given-names>G.</given-names></name><name><surname>Choknacki</surname><given-names>T.</given-names></name><name><surname>Swiezewska</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Distrinution and breakdown of labeled coenzyme Q10 in rats</article-title>. <source/>Free Radic. Biol. Med.
<volume>34</volume>, <fpage>563</fpage>–<lpage>575</lpage>. <pub-id pub-id-type="doi">10.1016/S0891-5849(02)01357-6</pub-id><pub-id pub-id-type="pmid">12614845</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentinger</surname><given-names>M.</given-names></name><name><surname>Tekle</surname><given-names>M.</given-names></name><name><surname>Dallner</surname><given-names>G.</given-names></name></person-group> (<year>2010</year>). <article-title>Coenzyme Q–biosynthesis and functions</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>396</volume>, <fpage>74</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2010.02.147</pub-id><pub-id pub-id-type="pmid">20494114</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>R. E.</given-names></name><name><surname>Burnett</surname><given-names>B. A.</given-names></name><name><surname>Cartwright</surname><given-names>K. J.</given-names></name><name><surname>Edington</surname><given-names>D. W.</given-names></name><name><surname>Falzon</surname><given-names>M. J.</given-names></name><name><surname>Kreitman</surname><given-names>K. R.</given-names></name><etal></etal></person-group>. (<year>1985</year>). <article-title>Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat</article-title>. <source/>Mech. Ageing Dev.
<volume>32</volume>, <fpage>267</fpage>–<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/0047-6374(85)90085-5</pub-id><pub-id pub-id-type="pmid">4087945</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhagavan</surname><given-names>H. N.</given-names></name><name><surname>Chopra</surname><given-names>R. K.</given-names></name></person-group> (<year>2006</year>). <article-title>Coenzyme Q10: absortion, tissue uptake, metabolism and pharmacokinetics</article-title>. <source/>Free Radic. Res.
<volume>40</volume>, <fpage>445</fpage>–<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1080/10715760600617843</pub-id><pub-id pub-id-type="pmid">16551570</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolignano</surname><given-names>D.</given-names></name><name><surname>Cernaro</surname><given-names>V.</given-names></name><name><surname>Gembillo</surname><given-names>G.</given-names></name><name><surname>Baggetta</surname><given-names>R.</given-names></name><name><surname>Buemi</surname><given-names>M.</given-names></name><name><surname>D'arrigo</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Antioxidant agents for delaying diabetic kidney disease progression: a systematic review and meta-analysis</article-title>. <source/>PLoS ONE
<volume>12</volume>:<fpage>e0178699</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0178699</pub-id><pub-id pub-id-type="pmid">28570649</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>A.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2016</year>). <article-title>Mitochondrial dysfunction in Parkinson's disease</article-title>. <source/>J. Neurochem.
<volume>139</volume>(<issue>Suppl. 1</issue>), <fpage>216</fpage>–<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13731</pub-id><pub-id pub-id-type="pmid">27546335</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brea-Calvo</surname><given-names>G.</given-names></name><name><surname>Siendones</surname><given-names>E.</given-names></name><name><surname>Sanchez-Alcazar</surname><given-names>J. A.</given-names></name><name><surname>De Cabo</surname><given-names>R.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Cell survival from chemotherapy depends on NF-kappaB transcriptional up-regulation of coenzyme Q biosynthesis</article-title>. <source/>PLoS ONE
<volume>4</volume>:<fpage>e5301</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0005301</pub-id><pub-id pub-id-type="pmid">19390650</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhmann</surname><given-names>C.</given-names></name><name><surname>Arlt</surname><given-names>S.</given-names></name><name><surname>Kontush</surname><given-names>A.</given-names></name><name><surname>Moller-Bertram</surname><given-names>T.</given-names></name><name><surname>Sperber</surname><given-names>S.</given-names></name><name><surname>Oechsner</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication</article-title>. <source/>Neurobiol. Dis.
<volume>15</volume>, <fpage>160</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2003.10.003</pub-id><pub-id pub-id-type="pmid">14751781</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campagnolo</surname><given-names>N.</given-names></name><name><surname>Johnston</surname><given-names>S.</given-names></name><name><surname>Collatz</surname><given-names>A.</given-names></name><name><surname>Staines</surname><given-names>D.</given-names></name><name><surname>Marshall-Gradisnik</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review</article-title>. <source/>J. Hum. Nutr. Diet.
<volume>30</volume>, <fpage>247</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1111/jhn.12435</pub-id><pub-id pub-id-type="pmid">28111818</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascajo</surname><given-names>M. V.</given-names></name><name><surname>Abdelmohsen</surname><given-names>K.</given-names></name><name><surname>Noh</surname><given-names>J. H.</given-names></name><name><surname>Fernandez-Ayala</surname><given-names>D. J.</given-names></name><name><surname>Willers</surname><given-names>I. M.</given-names></name><name><surname>Brea</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>RNA-binding proteins regulate cell respiration and coenzyme Q biosynthesis by post-transcriptional regulation of COQ7</article-title>. <source/>RNA Biol.
<volume>13</volume>, <fpage>622</fpage>–<lpage>634</lpage>. <pub-id pub-id-type="doi">10.1080/15476286.2015.1119366</pub-id><pub-id pub-id-type="pmid">26690054</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>F. L.</given-names></name><name><surname>Low</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>I.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>Gvozdjakova</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Plasma membrane coenzyme Q: evidence for a role in autism</article-title>. <source/>Biologics
<volume>8</volume>, <fpage>199</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.2147/BTT.S53375</pub-id><pub-id pub-id-type="pmid">24920882</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Cabo</surname><given-names>R.</given-names></name><name><surname>Cabello</surname><given-names>R.</given-names></name><name><surname>Rios</surname><given-names>M.</given-names></name><name><surname>López-Lluch</surname><given-names>G.</given-names></name><name><surname>Ingram</surname><given-names>D. K.</given-names></name><name><surname>Lane</surname><given-names>M. A.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Calorie restriction attenuates age-related alterations in the plasma membrane antioxidant system in rat liver</article-title>. <source/>Exp. Gerontol.
<volume>39</volume>, <fpage>297</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2003.12.003</pub-id><pub-id pub-id-type="pmid">15036389</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Frutos</surname><given-names>F.</given-names></name><name><surname>Gea</surname><given-names>A.</given-names></name><name><surname>Hernandez-Estefania</surname><given-names>R.</given-names></name><name><surname>Rabago</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Prophylactic treatment with coenzyme Q10 in patients undergoing cardiac surgery: could an antioxidant reduce complications? A systematic review and meta-analysis</article-title>. <source/>Interact. Cardiovasc. Thorac. Surg.
<volume>20</volume>, <fpage>254</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1093/icvts/ivu334</pub-id><pub-id pub-id-type="pmid">25344142</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Pozo-Cruz</surname><given-names>J.</given-names></name><name><surname>Rodriguez-Bies</surname><given-names>E.</given-names></name><name><surname>Ballesteros-Simarro</surname><given-names>M.</given-names></name><name><surname>Navas-Enamorado</surname><given-names>I.</given-names></name><name><surname>Tung</surname><given-names>B. T.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2014a</year>). <article-title>Physical activity affects plasma coenzyme Q10 levels differently in young and old humans</article-title>. <source/>Biogerontology
<volume>15</volume>, <fpage>199</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1007/s10522-013-9491-y</pub-id><pub-id pub-id-type="pmid">24384733</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Pozo-Cruz</surname><given-names>J.</given-names></name><name><surname>Rodriguez-Bies</surname><given-names>E.</given-names></name><name><surname>Navas-Enamorado</surname><given-names>I.</given-names></name><name><surname>Del Pozo-Cruz</surname><given-names>B.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>López-Lluch</surname><given-names>G.</given-names></name></person-group> (<year>2014b</year>). <article-title>Relationship between functional capacity and body mass index with plasma coenzyme Q10 and oxidative damage in community-dwelling elderly-people</article-title>. <source/>Exp. Gerontol.
<volume>52</volume>, <fpage>46</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2014.01.026</pub-id><pub-id pub-id-type="pmid">24512763</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desbats</surname><given-names>M. A.</given-names></name><name><surname>Lunardi</surname><given-names>G.</given-names></name><name><surname>Doimo</surname><given-names>M.</given-names></name><name><surname>Trevisson</surname><given-names>E.</given-names></name><name><surname>Salviati</surname><given-names>L.</given-names></name></person-group> (<year>2015a</year>). <article-title>Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency</article-title>. <source/>J. Inherit. Metab. Dis.
<volume>38</volume>, <fpage>145</fpage>–<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-014-9749-9</pub-id><pub-id pub-id-type="pmid">25091424</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desbats</surname><given-names>M. A.</given-names></name><name><surname>Morbidoni</surname><given-names>V.</given-names></name><name><surname>Silic-Benussi</surname><given-names>M.</given-names></name><name><surname>Doimo</surname><given-names>M.</given-names></name><name><surname>Ciminale</surname><given-names>V.</given-names></name><name><surname>Cassina</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>The COQ2 genotype predicts the severity of coenzyme Q10 deficiency</article-title>. <source/>Hum. Mol. Genet.
<volume>25</volume>, <fpage>4256</fpage>–<lpage>4265</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddw257</pub-id><pub-id pub-id-type="pmid">27493029</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desbats</surname><given-names>M. A.</given-names></name><name><surname>Vetro</surname><given-names>A.</given-names></name><name><surname>Limongelli</surname><given-names>I.</given-names></name><name><surname>Lunardi</surname><given-names>G.</given-names></name><name><surname>Casarin</surname><given-names>A.</given-names></name><name><surname>Doimo</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2015b</year>). <article-title>Primary coenzyme Q10 deficiency presenting as fatal neonatal multiorgan failure</article-title>. <source/>Eur. J. Hum. Genet.
<volume>23</volume>, <fpage>1254</fpage>–<lpage>1258</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2014.277</pub-id><pub-id pub-id-type="pmid">25564041</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doimo</surname><given-names>M.</given-names></name><name><surname>Desbats</surname><given-names>M. A.</given-names></name><name><surname>Cerqua</surname><given-names>C.</given-names></name><name><surname>Cassina</surname><given-names>M.</given-names></name><name><surname>Trevisson</surname><given-names>E.</given-names></name><name><surname>Salviati</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Genetics of coenzyme q10 deficiency</article-title>. <source/>Mol. Syndromol.
<volume>5</volume>, <fpage>156</fpage>–<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1159/000362826</pub-id><pub-id pub-id-type="pmid">25126048</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>G. C.</given-names></name><name><surname>Qin</surname><given-names>L. Q.</given-names></name><name><surname>Fu</surname><given-names>C. L.</given-names></name><name><surname>Chen</surname><given-names>L. H.</given-names></name></person-group> (<year>2017</year>). <article-title>Effects of coenzyme Q10 supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source/>Pharmacol. Res.
<volume>119</volume>, <fpage>128</fpage>–<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.01.032</pub-id><pub-id pub-id-type="pmid">28179205</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedacko</surname><given-names>J.</given-names></name><name><surname>Pella</surname><given-names>D.</given-names></name><name><surname>Fedackova</surname><given-names>P.</given-names></name><name><surname>Hanninen</surname><given-names>O.</given-names></name><name><surname>Tuomainen</surname><given-names>P.</given-names></name><name><surname>Jarcuska</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Coenzyme Q(10) and selenium in statin-associated myopathy treatment</article-title>. <source/>Can. J. Physiol. Pharmacol.
<volume>91</volume>, <fpage>165</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1139/cjpp-2012-0118</pub-id><pub-id pub-id-type="pmid">23458201</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A.</given-names></name><name><surname>Onur</surname><given-names>S.</given-names></name><name><surname>Niklowitz</surname><given-names>P.</given-names></name><name><surname>Menke</surname><given-names>T.</given-names></name><name><surname>Laudes</surname><given-names>M.</given-names></name><name><surname>Rimbach</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Coenzyme Q10 status as a determinant of muscular strength in two independent cohorts</article-title>. <source/>PLoS ONE
<volume>11</volume>:<fpage>e0167124</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0167124</pub-id><pub-id pub-id-type="pmid">27907044</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flowers</surname><given-names>N.</given-names></name><name><surname>Hartley</surname><given-names>L.</given-names></name><name><surname>Todkill</surname><given-names>D.</given-names></name><name><surname>Stranges</surname><given-names>S.</given-names></name><name><surname>Rees</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease</article-title>. <source/>Cochrane Database Syst. Rev. CD010405. <pub-id pub-id-type="doi">10.1002/14651858.CD010405.pub2</pub-id><pub-id pub-id-type="pmid">25474484</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floyd</surname><given-names>B. J.</given-names></name><name><surname>Wilkerson</surname><given-names>E. M.</given-names></name><name><surname>Veling</surname><given-names>M. T.</given-names></name><name><surname>Minogue</surname><given-names>C. E.</given-names></name><name><surname>Xia</surname><given-names>C.</given-names></name><name><surname>Beebe</surname><given-names>E. T.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Mitochondrial protein interaction mapping identifies regulators of respiratory chain function</article-title>. <source/>Mol. Cell
<volume>63</volume>, <fpage>621</fpage>–<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.033</pub-id><pub-id pub-id-type="pmid">27499296</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotino</surname><given-names>A. D.</given-names></name><name><surname>Thompson-Paul</surname><given-names>A. M.</given-names></name><name><surname>Bazzano</surname><given-names>L. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Effect of coenzyme Q(1)(0) supplementation on heart failure: a meta-analysis</article-title>. <source/>Am. J. Clin. Nutr.
<volume>97</volume>, <fpage>268</fpage>–<lpage>275</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.112.040741</pub-id><pub-id pub-id-type="pmid">23221577</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freyer</surname><given-names>C.</given-names></name><name><surname>Stranneheim</surname><given-names>H.</given-names></name><name><surname>Naess</surname><given-names>K.</given-names></name><name><surname>Mourier</surname><given-names>A.</given-names></name><name><surname>Felser</surname><given-names>A.</given-names></name><name><surname>Maffezzini</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybensoic acid</article-title>. <source/>J. Med. Genet.
<volume>52</volume>, <fpage>779</fpage>–<lpage>783</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2015-102986</pub-id><pub-id pub-id-type="pmid">26084283</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galasko</surname><given-names>D. R.</given-names></name><name><surname>Peskind</surname><given-names>E.</given-names></name><name><surname>Clark</surname><given-names>C. M.</given-names></name><name><surname>Quinn</surname><given-names>J. F.</given-names></name><name><surname>Ringman</surname><given-names>J. M.</given-names></name><name><surname>Jicha</surname><given-names>G. A.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures</article-title>. <source/>Arch. Neurol.
<volume>69</volume>, <fpage>836</fpage>–<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1001/archneurol.2012.85</pub-id><pub-id pub-id-type="pmid">22431837</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genova</surname><given-names>M. L.</given-names></name><name><surname>Lenaz</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Functional role of mitochondrial respiratory supercomplexes</article-title>. <source/>Biochim. Biophys. Acta
<volume>1837</volume>, <fpage>427</fpage>–<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2013.11.002</pub-id><pub-id pub-id-type="pmid">24246637</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gigante</surname><given-names>M.</given-names></name><name><surname>Diella</surname><given-names>S.</given-names></name><name><surname>Santangelo</surname><given-names>L.</given-names></name><name><surname>Trevisson</surname><given-names>E.</given-names></name><name><surname>Acosta</surname><given-names>M. J.</given-names></name><name><surname>Amatruda</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Further phenotypic heterogeneity of CoQ10 deficiency associated with steroid resistant nephrotic syndrome and novel COQ2 and COQ6 variants</article-title>. <source/>Clin. Genet.
<volume>92</volume>, <fpage>224</fpage>–<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1111/cge.12960</pub-id><pub-id pub-id-type="pmid">28044327</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Guardia</surname><given-names>L.</given-names></name><name><surname>Yubero-Serrano</surname><given-names>E. M.</given-names></name><name><surname>Delgado-Lista</surname><given-names>J.</given-names></name><name><surname>Perez-Martinez</surname><given-names>P.</given-names></name><name><surname>Garcia-Rios</surname><given-names>A.</given-names></name><name><surname>Marin</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Effects of the Mediterranean diet supplemented with coenzyme q10 on metabolomic profiles in elderly men and women</article-title>. <source/>J. Gerontol. A Biol. Sci. Med. Sci.
<volume>70</volume>, <fpage>78</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/glu098</pub-id><pub-id pub-id-type="pmid">24986061</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorman</surname><given-names>G. S.</given-names></name><name><surname>Chinnery</surname><given-names>P. F.</given-names></name><name><surname>Dimauro</surname><given-names>S.</given-names></name><name><surname>Hirano</surname><given-names>M.</given-names></name><name><surname>Koga</surname><given-names>Y.</given-names></name><name><surname>Mcfarland</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Mitochondrial diseases</article-title>. <source/>Nat. Rev. Dis. Primers
<volume>2</volume>:<fpage>16080</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2016.80</pub-id><pub-id pub-id-type="pmid">27775730</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>A.</given-names></name><name><surname>Friedland</surname><given-names>K.</given-names></name><name><surname>Eckert</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease</article-title>. <source/>Biogerontology
<volume>17</volume>, <fpage>281</fpage>–<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1007/s10522-015-9618-4</pub-id><pub-id pub-id-type="pmid">26468143</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guaras</surname><given-names>A.</given-names></name><name><surname>Perales-Clemente</surname><given-names>E.</given-names></name><name><surname>Calvo</surname><given-names>E.</given-names></name><name><surname>Acin-Perez</surname><given-names>R.</given-names></name><name><surname>Loureiro-Lopez</surname><given-names>M.</given-names></name><name><surname>Pujol</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>The CoQH2/CoQ ratio serves as a sensor of respiratory chain efficiency</article-title>. <source/>Cell Rep.
<volume>15</volume>, <fpage>197</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.009</pub-id><pub-id pub-id-type="pmid">27052170</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Zong</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Architecture of human mitochondrial respiratory megacomplex I2III2IV2</article-title>. <source/>Cell
<volume>170</volume>, <fpage>1247 e1212</fpage>–<lpage>1257 e1212</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.07.050</pub-id><pub-id pub-id-type="pmid">28844695</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gvozdjakova</surname><given-names>A.</given-names></name><name><surname>Kucharska</surname><given-names>J.</given-names></name><name><surname>Dubravicky</surname><given-names>J.</given-names></name><name><surname>Mojto</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>R. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Coenzyme Q(1)(0), alpha-tocopherol, and oxidative stress could be important metabolic biomarkers of male infertility</article-title>. <source/>Dis. Markers
<volume>2015</volume>:<fpage>827941</fpage>
<pub-id pub-id-type="doi">10.1155/2015/827941</pub-id><pub-id pub-id-type="pmid">25810566</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gvozdjakova</surname><given-names>A.</given-names></name><name><surname>Kucharska</surname><given-names>J.</given-names></name><name><surname>Ostatnikova</surname><given-names>D.</given-names></name><name><surname>Babinska</surname><given-names>K.</given-names></name><name><surname>Nakladal</surname><given-names>D.</given-names></name><name><surname>Crane</surname><given-names>F. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Ubiquinol improves symptoms in children with autism</article-title>. <source/>Oxid. Med. Cell. Longev.
<volume>2014</volume>:<fpage>798957</fpage>. <pub-id pub-id-type="doi">10.1155/2014/798957</pub-id><pub-id pub-id-type="pmid">24707344</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>S. J.</given-names></name><name><surname>Chew</surname><given-names>G. T.</given-names></name><name><surname>Watts</surname><given-names>G. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients</article-title>. <source/>Diabetes Care
<volume>32</volume>, <fpage>810</fpage>–<lpage>812</lpage>. <pub-id pub-id-type="doi">10.2337/dc08-1736</pub-id><pub-id pub-id-type="pmid">19228872</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hathcock</surname><given-names>J. N.</given-names></name><name><surname>Shao</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>Risk assessment for coenzyme Q10 (Ubiquinone)</article-title>. <source/>Regul. Toxicol. Pharmacol.
<volume>45</volume>, <fpage>282</fpage>–<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2006.05.006</pub-id><pub-id pub-id-type="pmid">16814438</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>C. H.</given-names></name><name><surname>Black</surname><given-names>D. S.</given-names></name><name><surname>Allan</surname><given-names>C. M.</given-names></name><name><surname>Meunier</surname><given-names>B.</given-names></name><name><surname>Rahman</surname><given-names>S.</given-names></name><name><surname>Clarke</surname><given-names>C. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Human COQ9 rescues a coq9 yeast mutant by enhancing coenzyme Q biosynthesis from 4-hydroxybenzoic acid and stabilizing the CoQ-synthome</article-title>. <source/>Front. Physiol.
<volume>8</volume>:<fpage>463</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.00463</pub-id><pub-id pub-id-type="pmid">28736527</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>C. H.</given-names></name><name><surname>Xie</surname><given-names>L. X.</given-names></name><name><surname>Allan</surname><given-names>C. M.</given-names></name><name><surname>Tran</surname><given-names>U. C.</given-names></name><name><surname>Clarke</surname><given-names>C. F.</given-names></name></person-group> (<year>2014</year>). <article-title>Coenzyme Q supplementation or over-expression of the yeast Coq8 putative kinase stabilizes multi-subunit Coq polypeptide complexes in yeast coq null mutants</article-title>. <source/>Biochim. Biophys. Acta
<volume>1841</volume>, <fpage>630</fpage>–<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2013.12.017</pub-id><pub-id pub-id-type="pmid">24406904</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeringa</surname><given-names>S. F.</given-names></name><name><surname>Chernin</surname><given-names>G.</given-names></name><name><surname>Chaki</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Sloan</surname><given-names>A. J.</given-names></name><name><surname>Ji</surname><given-names>Z.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness</article-title>. <source/>J. Clin. Invest.
<volume>121</volume>, <fpage>2013</fpage>–<lpage>2024</lpage>. <pub-id pub-id-type="doi">10.1172/JCI45693</pub-id><pub-id pub-id-type="pmid">21540551</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>A.</given-names></name><name><surname>Kawarazaki</surname><given-names>H.</given-names></name><name><surname>Ando</surname><given-names>K.</given-names></name><name><surname>Fujita</surname><given-names>M.</given-names></name><name><surname>Fujita</surname><given-names>T.</given-names></name><name><surname>Homma</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Renal preservation effect of ubiquinol, the reduced form of coenzyme Q10</article-title>. <source/>Clin. Exp. Nephrol.
<volume>15</volume>, <fpage>30</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1007/s10157-010-0350-8</pub-id><pub-id pub-id-type="pmid">20878200</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishrat</surname><given-names>T.</given-names></name><name><surname>Khan</surname><given-names>M. B.</given-names></name><name><surname>Hoda</surname><given-names>M. N.</given-names></name><name><surname>Yousuf</surname><given-names>S.</given-names></name><name><surname>Ahmad</surname><given-names>M.</given-names></name><name><surname>Ansari</surname><given-names>M. A.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats</article-title>. <source/>Behav. Brain Res.
<volume>171</volume>, <fpage>9</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2006.03.009</pub-id><pub-id pub-id-type="pmid">16621054</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakobs</surname><given-names>B. S.</given-names></name><name><surname>Van Den Heuvel</surname><given-names>L. P.</given-names></name><name><surname>Smeets</surname><given-names>R. J.</given-names></name><name><surname>De Vries</surname><given-names>M. C.</given-names></name><name><surname>Hien</surname><given-names>S.</given-names></name><name><surname>Schaible</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>A novel mutation in COQ2 leading to fatal infantile multisystem disease</article-title>. <source/>J. Neurol. Sci.
<volume>326</volume>, <fpage>24</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2013.01.004</pub-id><pub-id pub-id-type="pmid">23343605</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>P.</given-names></name><name><surname>Dahlstrom</surname><given-names>O.</given-names></name><name><surname>Dahlstrom</surname><given-names>U.</given-names></name><name><surname>Alehagen</surname><given-names>U.</given-names></name></person-group> (<year>2015</year>). <article-title>Improved health-related quality of life, and more days out of hospital with supplementation with selenium and coenzyme Q10 combined. Results from a double blind, placebo-controlled prospective study</article-title>. <source/>J. Nutr. Health Aging
<volume>19</volume>, <fpage>870</fpage>–<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1007/s12603-015-0509-9</pub-id><pub-id pub-id-type="pmid">26482687</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalen</surname><given-names>A.</given-names></name><name><surname>Appelkvist</surname><given-names>E. L.</given-names></name><name><surname>Dallner</surname><given-names>G.</given-names></name></person-group> (<year>1989</year>). <article-title>Age-related changes in the lipid compositions of rat and human tissues</article-title>. <source/>Lipids
<volume>24</volume>, <fpage>579</fpage>–<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1007/BF02535072</pub-id><pub-id pub-id-type="pmid">2779364</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamukai</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Biosynthesis of coenzyme Q in eukaryotes</article-title>. <source/>Biosci. Biotechnol. Biochem.
<volume>80</volume>, <fpage>23</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1080/09168451.2015.1065172</pub-id><pub-id pub-id-type="pmid">26183239</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafuente</surname><given-names>R.</given-names></name><name><surname>Gonzalez-Comadran</surname><given-names>M.</given-names></name><name><surname>Sola</surname><given-names>I.</given-names></name><name><surname>Lopez</surname><given-names>G.</given-names></name><name><surname>Brassesco</surname><given-names>M.</given-names></name><name><surname>Carreras</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Coenzyme Q10 and male infertility: a meta-analysis</article-title>. <source/>J. Assist. Reprod. Genet.
<volume>30</volume>, <fpage>1147</fpage>–<lpage>1156</lpage>. <pub-id pub-id-type="doi">10.1007/s10815-013-0047-5</pub-id><pub-id pub-id-type="pmid">23912751</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapointe</surname><given-names>J.</given-names></name><name><surname>Hekimi</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Early mitochondrial dysfunction in long-lived Mclk1+/- mice</article-title>. <source/>J. Biol. Chem.
<volume>283</volume>, <fpage>26217</fpage>–<lpage>26227</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M803287200</pub-id><pub-id pub-id-type="pmid">18635541</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapuente-Brun</surname><given-names>E.</given-names></name><name><surname>Moreno-Loshuertos</surname><given-names>R.</given-names></name><name><surname>Acin-Perez</surname><given-names>R.</given-names></name><name><surname>Latorre-Pellicer</surname><given-names>A.</given-names></name><name><surname>Colas</surname><given-names>C.</given-names></name><name><surname>Balsa</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Supercomplex assembly determines electron flux in the mitochondrial electron transport chain</article-title>. <source/>Science
<volume>340</volume>, <fpage>1567</fpage>–<lpage>1570</lpage>. <pub-id pub-id-type="doi">10.1126/science.1230381</pub-id><pub-id pub-id-type="pmid">23812712</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laredj</surname><given-names>L. N.</given-names></name><name><surname>Licitra</surname><given-names>F.</given-names></name><name><surname>Puccio</surname><given-names>H. M.</given-names></name></person-group> (<year>2014</year>). <article-title>The molecular genetics of coenzyme Q biosynthesis in health and disease</article-title>. <source/>Biochimie
<volume>100</volume>, <fpage>78</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.biochi.2013.12.006</pub-id><pub-id pub-id-type="pmid">24355204</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>M.</given-names></name><name><surname>Rudnicka</surname><given-names>A. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Statin safety: a systematic review</article-title>. <source/>Am. J. Cardiol.
<volume>97</volume>, <fpage>52C</fpage>–<lpage>60C</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2005.12.010</pub-id><pub-id pub-id-type="pmid">16581329</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littarru</surname><given-names>G. P.</given-names></name><name><surname>Langsjoen</surname><given-names>P.</given-names></name></person-group> (<year>2007</year>). <article-title>Coenzyme Q10 and statins: biochemical and clinical implications</article-title>. <source/>Mitochondrion
<volume>7</volume>(<issue>Suppl.</issue>), <fpage>S168</fpage>–<lpage>S174</lpage>. <pub-id pub-id-type="doi">10.1016/j.mito.2007.03.002</pub-id><pub-id pub-id-type="pmid">17482884</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone</article-title>. <source/>CNS Drugs
<volume>28</volume>, <fpage>63</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1007/s40263-013-0124-4</pub-id><pub-id pub-id-type="pmid">24242074</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhan</surname><given-names>S. Y.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Coenzyme Q10 for Parkinson's disease</article-title>. <source/>Cochrane Database Syst. Rev. CD008150. <pub-id pub-id-type="doi">10.1002/14651858.CD008150.pub2</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Lluch</surname><given-names>G.</given-names></name><name><surname>Rios</surname><given-names>M.</given-names></name><name><surname>Lane</surname><given-names>M. A.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>De Cabo</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>Mouse liver plasma membrane redox system activity is altered by aging and modulated by calorie restriction</article-title>. <source/>Age
<volume>27</volume>, <fpage>153</fpage>–<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-005-2726-3</pub-id><pub-id pub-id-type="pmid">23598622</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Lluch</surname><given-names>G.</given-names></name><name><surname>Rodriguez-Aguilera</surname><given-names>J. C.</given-names></name><name><surname>Santos-Ocana</surname><given-names>C.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Is coenzyme Q a key factor in aging?</article-title>
<source/>Mech. Ageing Dev.
<volume>131</volume>, <fpage>225</fpage>–<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.mad.2010.02.003</pub-id><pub-id pub-id-type="pmid">20193705</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madmani</surname><given-names>M. E.</given-names></name><name><surname>Yusuf Solaiman</surname><given-names>A.</given-names></name><name><surname>Tamr Agha</surname><given-names>K.</given-names></name><name><surname>Madmani</surname><given-names>Y.</given-names></name><name><surname>Shahrour</surname><given-names>Y.</given-names></name><name><surname>Essali</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Coenzyme Q10 for heart failure</article-title>. <source/>Cochrane Database Syst. Rev. CD008684. <pub-id pub-id-type="doi">10.1002/14651858.CD008684.pub2</pub-id><pub-id pub-id-type="pmid">24049047</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Montalvo</surname><given-names>A.</given-names></name><name><surname>Gonzalez-Mariscal</surname><given-names>I.</given-names></name><name><surname>Padilla</surname><given-names>S.</given-names></name><name><surname>Ballesteros</surname><given-names>M.</given-names></name><name><surname>Brautigan</surname><given-names>D. L.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Respiratory-induced coenzyme Q biosynthesis is regulated by a phosphorylation cycle of Cat5p/Coq7p</article-title>. <source/>Biochem. J.
<volume>440</volume>, <fpage>107</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20101422</pub-id><pub-id pub-id-type="pmid">21812761</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Montalvo</surname><given-names>A.</given-names></name><name><surname>Gonzalez-Mariscal</surname><given-names>I.</given-names></name><name><surname>Pomares-Viciana</surname><given-names>T.</given-names></name><name><surname>Padilla-Lopez</surname><given-names>S.</given-names></name><name><surname>Ballesteros</surname><given-names>M.</given-names></name><name><surname>Vazquez-Fonseca</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>The phosphatase Ptc7 induces coenzyme Q biosynthesis by activating the hydroxylase Coq7 in yeast</article-title>. <source/>J. Biol. Chem.
<volume>288</volume>, <fpage>28126</fpage>–<lpage>28137</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.474494</pub-id><pub-id pub-id-type="pmid">23940037</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Montalvo</surname><given-names>A.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Diaz-Ruiz</surname><given-names>A.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><name><surname>Gutierrez</surname><given-names>V.</given-names></name><name><surname>Palacios</surname><given-names>H. H.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Cytochrome b5 reductase and the control of lipid metabolism and healthspan</article-title>. <source/>NPJ Aging Mech. Dis.
<volume>2</volume>:<fpage>16006</fpage>. <pub-id pub-id-type="doi">10.1038/npjamd.2016.6</pub-id><pub-id pub-id-type="pmid">28721264</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazidi</surname><given-names>M.</given-names></name><name><surname>Kengne</surname><given-names>A. P.</given-names></name><name><surname>Banach</surname><given-names>M.</given-names></name><name><surname>Lipid</surname></name><collab>Blood Pressure Meta-Analysis Collaboration, G.</collab></person-group> (<year>2017</year>). <article-title>Effects of coenzyme Q10 supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials</article-title>. <source/>Pharmacol. Res. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.08.011</pub-id><pub-id pub-id-type="pmid">28847708</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGarry</surname><given-names>A.</given-names></name><name><surname>McDermott</surname><given-names>M.</given-names></name><name><surname>Kieburtz</surname><given-names>K.</given-names></name><name><surname>De Blieck</surname><given-names>E. A.</given-names></name><name><surname>Beal</surname><given-names>F.</given-names></name><name><surname>Marder</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease</article-title>. <source/>Neurology
<volume>88</volume>, <fpage>152</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000003478</pub-id><pub-id pub-id-type="pmid">27913695</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milenkovic</surname><given-names>D.</given-names></name><name><surname>Blaza</surname><given-names>J. N.</given-names></name><name><surname>Larsson</surname><given-names>N. G.</given-names></name><name><surname>Hirst</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>The enigma of the respiratory chain supercomplex</article-title>. <source/>Cell Metab.
<volume>25</volume>, <fpage>765</fpage>–<lpage>776</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2017.03.009</pub-id><pub-id pub-id-type="pmid">28380371</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mischley</surname><given-names>L. K.</given-names></name><name><surname>Allen</surname><given-names>J.</given-names></name><name><surname>Bradley</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Coenzyme Q10 deficiency in patients with Parkinson's disease</article-title>. <source/>J. Neurol. Sci.
<volume>318</volume>, <fpage>72</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2012.03.023</pub-id><pub-id pub-id-type="pmid">22542608</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molyneux</surname><given-names>S.</given-names></name><name><surname>Florkowski</surname><given-names>C.</given-names></name><name><surname>Lever</surname><given-names>M.</given-names></name><name><surname>George</surname><given-names>P.</given-names></name></person-group> (<year>2004</year>). <article-title>The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly</article-title>. <source/>N. Z. Med. J.
<volume>117</volume>, <fpage>U1108</fpage>. <pub-id pub-id-type="pmid">15477929</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montini</surname><given-names>G.</given-names></name><name><surname>Malaventura</surname><given-names>C.</given-names></name><name><surname>Salviati</surname><given-names>L.</given-names></name></person-group> (<year>2008</year>). <article-title>Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency</article-title>. <source/>N. Engl. J. Med.
<volume>358</volume>, <fpage>2849</fpage>–<lpage>2850</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc0800582</pub-id><pub-id pub-id-type="pmid">18579827</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moradi</surname><given-names>M.</given-names></name><name><surname>Haghighatdoost</surname><given-names>F.</given-names></name><name><surname>Feizi</surname><given-names>A.</given-names></name><name><surname>Larijani</surname><given-names>B.</given-names></name><name><surname>Azadbakht</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Effect of coenzyme Q10 supplementation on diabetes biomarkers: a systematic review and meta-analysis of randomized controlled clinical trials</article-title>. <source/>Arch. Iran. Med.
<volume>19</volume>, <fpage>588</fpage>–<lpage>596</lpage>. <pub-id pub-id-type="pmid">27544369</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgenstern</surname><given-names>M.</given-names></name><name><surname>Stiller</surname><given-names>S. B.</given-names></name><name><surname>Lubbert</surname><given-names>P.</given-names></name><name><surname>Peikert</surname><given-names>C. D.</given-names></name><name><surname>Dannenmaier</surname><given-names>S.</given-names></name><name><surname>Drepper</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Definition of a high-confidence mitochondrial proteome at quantitative scale</article-title>. <source/>Cell Rep.
<volume>19</volume>, <fpage>2836</fpage>–<lpage>2852</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.014</pub-id><pub-id pub-id-type="pmid">28658629</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>S. A.</given-names></name><name><surname>Rosenfeldt</surname><given-names>F.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Dolliner</surname><given-names>P.</given-names></name><name><surname>Filipiak</surname><given-names>K. J.</given-names></name><name><surname>Pella</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial</article-title>. <source/>JACC Heart Fail.
<volume>2</volume>, <fpage>641</fpage>–<lpage>649</lpage>. <pub-id pub-id-type="doi">10.1016/j.jchf.2014.06.008</pub-id><pub-id pub-id-type="pmid">25282031</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>Villalba</surname><given-names>J. M.</given-names></name><name><surname>De Cabo</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>The importance of plasma membrane coenzyme Q in aging and stress responses</article-title>. <source/>Mitochondrion
<volume>7</volume>(<issue>Suppl.</issue>), <fpage>S34</fpage>–<lpage>S40</lpage>. <pub-id pub-id-type="doi">10.1016/j.mito.2007.02.010</pub-id><pub-id pub-id-type="pmid">17482527</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negida</surname><given-names>A.</given-names></name><name><surname>Menshawy</surname><given-names>A.</given-names></name><name><surname>El Ashal</surname><given-names>G.</given-names></name><name><surname>Elfouly</surname><given-names>Y.</given-names></name><name><surname>Hani</surname><given-names>Y.</given-names></name><name><surname>Hegazy</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Coenzyme Q10 for patients with parkinson's disease: a systematic review and meta-analysis</article-title>. <source/>CNS Neurol. Disord. Drug Targets
<volume>15</volume>, <fpage>45</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.2174/1871527314666150821103306</pub-id><pub-id pub-id-type="pmid">26553164</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Sanchez</surname><given-names>C.</given-names></name><name><surname>Aguirre</surname><given-names>M. A.</given-names></name><name><surname>Ruiz-Limon</surname><given-names>P.</given-names></name><name><surname>Abalos-Aguilera</surname><given-names>M. C.</given-names></name><name><surname>Jimenez-Gomez</surname><given-names>Y.</given-names></name><name><surname>Arias-De La Rosa</surname><given-names>I.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: a randomized, placebo-controlled trial</article-title>. <source/>Arterioscler. Thromb. Vasc. Biol.
<volume>37</volume>, <fpage>1923</fpage>–<lpage>1932</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309225</pub-id><pub-id pub-id-type="pmid">28684614</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pineda</surname><given-names>M.</given-names></name><name><surname>Montero</surname><given-names>R.</given-names></name><name><surname>Aracil</surname><given-names>A.</given-names></name><name><surname>O'callaghan</surname><given-names>M. M.</given-names></name><name><surname>Mas</surname><given-names>A.</given-names></name><name><surname>Espinos</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up</article-title>. <source/>Mov. Disord.
<volume>25</volume>, <fpage>1262</fpage>–<lpage>1268</lpage>. <pub-id pub-id-type="doi">10.1002/mds.23129</pub-id><pub-id pub-id-type="pmid">20629161</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirro</surname><given-names>M.</given-names></name><name><surname>Mannarino</surname><given-names>M. R.</given-names></name><name><surname>Bianconi</surname><given-names>V.</given-names></name><name><surname>Simental-Mendia</surname><given-names>L. E.</given-names></name><name><surname>Bagaglia</surname><given-names>F.</given-names></name><name><surname>Mannarino</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source/>Pharmacol. Res.
<volume>110</volume>, <fpage>76</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2016.04.021</pub-id><pub-id pub-id-type="pmid">27157250</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivara</surname><given-names>M. B.</given-names></name><name><surname>Yeung</surname><given-names>C. K.</given-names></name><name><surname>Robinson-Cohen</surname><given-names>C.</given-names></name><name><surname>Phillips</surname><given-names>B. R.</given-names></name><name><surname>Ruzinski</surname><given-names>J.</given-names></name><name><surname>Rock</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Effect of coenzyme Q10 on biomarkers of oxidative stress and cardiac function in hemodialysis patients: the CoQ10 biomarker trial</article-title>. <source/>Am. J. Kidney Dis.
<volume>69</volume>, <fpage>389</fpage>–<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2016.08.041</pub-id><pub-id pub-id-type="pmid">27927588</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Aguilera</surname><given-names>J. C.</given-names></name><name><surname>Cortes</surname><given-names>A. B.</given-names></name><name><surname>Fernandez-Ayala</surname><given-names>D. J.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Biochemical assessment of coenzyme Q<sub>10</sub> deficiency</article-title>. <source/>J. Clin. Med.
<volume>6</volume>:<fpage>E27</fpage>. <pub-id pub-id-type="doi">10.3390/jcm6030027</pub-id><pub-id pub-id-type="pmid">28273876</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>D.</given-names></name><name><surname>Siegel</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Functions of NQO1 in cellular protection and CoQ10 metabolism and its potential role as a redox sensitive molecular switch</article-title>. <source/>Front. Physiol.
<volume>8</volume>:<fpage>595</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.00595</pub-id><pub-id pub-id-type="pmid">28883796</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>D. A.</given-names></name><name><surname>Frye</surname><given-names>R. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis</article-title>. <source/>Mol. Psychiatry
<volume>17</volume>, <fpage>290</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2010.136</pub-id><pub-id pub-id-type="pmid">21263444</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safarinejad</surname><given-names>M. R.</given-names></name><name><surname>Safarinejad</surname><given-names>S.</given-names></name><name><surname>Shafiei</surname><given-names>N.</given-names></name><name><surname>Safarinejad</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study</article-title>. <source/>J. Urol.
<volume>188</volume>, <fpage>526</fpage>–<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2012.03.131</pub-id><pub-id pub-id-type="pmid">22704112</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahebkar</surname><given-names>A.</given-names></name><name><surname>Simental-Mendia</surname><given-names>L. E.</given-names></name><name><surname>Stefanutti</surname><given-names>C.</given-names></name><name><surname>Pirro</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis</article-title>. <source/>Pharmacol. Res.
<volume>105</volume>, <fpage>198</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2016.01.030</pub-id><pub-id pub-id-type="pmid">26836888</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saiki</surname><given-names>R.</given-names></name><name><surname>Lunceford</surname><given-names>A. L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Marbois</surname><given-names>B.</given-names></name><name><surname>King</surname><given-names>R.</given-names></name><name><surname>Pachuski</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Coenzyme Q10 supplementation rescues renal disease in Pdss2kd/kd mice with mutations in prenyl diphosphate synthase subunit 2</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>295</volume>, <fpage>F1535</fpage>–<lpage>F1544</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.90445.2008</pub-id><pub-id pub-id-type="pmid">18784258</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Salviati</surname><given-names>L.</given-names></name><name><surname>Trevisson</surname><given-names>E.</given-names></name><name><surname>Doimo</surname><given-names>M.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Primary Coenzyme Q10 Deficiency</article-title>, in <source/>GeneReviews(R), eds <person-group person-group-type="editor"><name><surname>Pagon</surname><given-names>R. A.</given-names></name><name><surname>Adam</surname><given-names>M. P.</given-names></name><name><surname>Ardinger</surname><given-names>H. H.</given-names></name><name><surname>Wallace</surname><given-names>S. E.</given-names></name><name><surname>Amemiya</surname><given-names>A.</given-names></name><name><surname>Bean</surname><given-names>L. J. H.</given-names></name><etal></etal></person-group> (<publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington</publisher-name>).</mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salviati</surname><given-names>L.</given-names></name><name><surname>Trevisson</surname><given-names>E.</given-names></name><name><surname>Rodriguez Hernandez</surname><given-names>M. A.</given-names></name><name><surname>Casarin</surname><given-names>A.</given-names></name><name><surname>Pertegato</surname><given-names>V.</given-names></name><name><surname>Doimo</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency</article-title>. <source/>J. Med. Genet.
<volume>49</volume>, <fpage>187</fpage>–<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2011-100394</pub-id><pub-id pub-id-type="pmid">22368301</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Ocana</surname><given-names>C.</given-names></name><name><surname>Do</surname><given-names>T. Q.</given-names></name><name><surname>Padilla</surname><given-names>S.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>Clarke</surname><given-names>C. F.</given-names></name></person-group> (<year>2002</year>). <article-title>Uptake of exogenous coenzyme Q and transport to mitochondria is required for bc1 complex stability in yeast coq mutants</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>10973</fpage>–<lpage>10981</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112222200</pub-id><pub-id pub-id-type="pmid">11788608</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirris</surname><given-names>T. J.</given-names></name><name><surname>Renkema</surname><given-names>G. H.</given-names></name><name><surname>Ritschel</surname><given-names>T.</given-names></name><name><surname>Voermans</surname><given-names>N. C.</given-names></name><name><surname>Bilos</surname><given-names>A.</given-names></name><name><surname>Van Engelen</surname><given-names>B. G.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Statin-induced myopathy is associated with mitochondrial complex III inhibition</article-title>. <source/>Cell Metab.
<volume>22</volume>, <fpage>399</fpage>–<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2015.08.002</pub-id><pub-id pub-id-type="pmid">26331605</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmelzer</surname><given-names>C.</given-names></name><name><surname>Kubo</surname><given-names>H.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Sawashita</surname><given-names>J.</given-names></name><name><surname>Kitano</surname><given-names>M.</given-names></name><name><surname>Hosoe</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Supplementation with the reduced form of Coenzyme Q10 decelerates phenotypic characteristics of senescence and induces a peroxisome proliferator-activated receptor-alpha gene expression signature in SAMP1 mice</article-title>. <source/>Mol. Nutr. Food Res.
<volume>54</volume>, <fpage>805</fpage>–<lpage>815</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.200900155</pub-id><pub-id pub-id-type="pmid">19960455</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>J. B.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>1995</year>). <article-title>Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease</article-title>. <source/>Ann. N. Y. Acad. Sci.
<volume>765</volume>, <fpage>100</fpage>–<lpage>110</lpage>. discussion: 116–108. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1995.tb16565.x</pub-id><pub-id pub-id-type="pmid">7486598</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scialo</surname><given-names>F.</given-names></name><name><surname>Sriram</surname><given-names>A.</given-names></name><name><surname>Fernandez-Ayala</surname><given-names>D.</given-names></name><name><surname>Gubina</surname><given-names>N.</given-names></name><name><surname>Lohmus</surname><given-names>M.</given-names></name><name><surname>Nelson</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Mitochondrial ROS produced via reverse electron transport extend animal lifespan</article-title>. <source/>Cell Metab.
<volume>23</volume>, <fpage>725</fpage>–<lpage>734</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.03.009</pub-id><pub-id pub-id-type="pmid">27076081</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shults</surname><given-names>C. W.</given-names></name></person-group> (<year>2003</year>). <article-title>Coenzyme Q10 in neurodegenerative diseases</article-title>. <source/>Curr. Med. Chem.
<volume>10</volume>, <fpage>1917</fpage>–<lpage>1921</lpage>. <pub-id pub-id-type="doi">10.2174/0929867033456882</pub-id><pub-id pub-id-type="pmid">12871093</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>M. A.</given-names></name><name><surname>Langsjoen</surname><given-names>P. H.</given-names></name><name><surname>Szabo</surname><given-names>S.</given-names></name><name><surname>Patil</surname><given-names>H.</given-names></name><name><surname>Zelinger</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction</article-title>. <source/>Am. J. Cardiol.
<volume>94</volume>, <fpage>1306</fpage>–<lpage>1310</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2004.07.121</pub-id><pub-id pub-id-type="pmid">15541254</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sondheimer</surname><given-names>N.</given-names></name><name><surname>Hewson</surname><given-names>S.</given-names></name><name><surname>Cameron</surname><given-names>J. M.</given-names></name><name><surname>Somers</surname><given-names>G. R.</given-names></name><name><surname>Broadbent</surname><given-names>J. D.</given-names></name><name><surname>Ziosi</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ10 deficiency</article-title>. <source/>Mol. Genet. Metab. Rep.
<volume>12</volume>, <fpage>23</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgmr.2017.05.001</pub-id><pub-id pub-id-type="pmid">28540186</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suksomboon</surname><given-names>N.</given-names></name><name><surname>Poolsup</surname><given-names>N.</given-names></name><name><surname>Juanak</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis</article-title>. <source/>J. Clin. Pharm. Ther.
<volume>40</volume>, <fpage>413</fpage>–<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1111/jcpt.12280</pub-id><pub-id pub-id-type="pmid">25913756</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>S. R.</given-names></name><name><surname>Neuzil</surname><given-names>J.</given-names></name><name><surname>Stocker</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis?</article-title>
<source/>Mol. Aspects Med.
<volume>18</volume>(<issue>Suppl.</issue>), <fpage>S85</fpage>–<lpage>S103</lpage>. <pub-id pub-id-type="pmid">9266510</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>P. D.</given-names></name><name><surname>Clarkson</surname><given-names>P.</given-names></name><name><surname>Karas</surname><given-names>R. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Statin-associated myopathy</article-title>. <source/>JAMA
<volume>289</volume>, <fpage>1681</fpage>–<lpage>1690</lpage>. <pub-id pub-id-type="doi">10.1001/jama.289.13.1681</pub-id><pub-id pub-id-type="pmid">12672737</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>G.</given-names></name><name><surname>Sawashita</surname><given-names>J.</given-names></name><name><surname>Kubo</surname><given-names>H.</given-names></name><name><surname>Nishio</surname><given-names>S. Y.</given-names></name><name><surname>Hashimoto</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Ubiquinol-10 supplementation activates mitochondria functions to decelerate senescence in senescence-accelerated mice</article-title>. <source/>Antioxid. Redox Signal.
<volume>20</volume>, <fpage>2606</fpage>–<lpage>2620</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2013.5406</pub-id><pub-id pub-id-type="pmid">24124769</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiano</surname><given-names>L.</given-names></name><name><surname>Busciglio</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q(10) ?</article-title>
<source/>Biofactors
<volume>37</volume>, <fpage>386</fpage>–<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1002/biof.184</pub-id><pub-id pub-id-type="pmid">22009852</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiano</surname><given-names>L.</given-names></name><name><surname>Carnevali</surname><given-names>P.</given-names></name><name><surname>Padella</surname><given-names>L.</given-names></name><name><surname>Santoro</surname><given-names>L.</given-names></name><name><surname>Principi</surname><given-names>F.</given-names></name><name><surname>Bruge</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Effect of coenzyme Q10 in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial</article-title>. <source/>Neurobiol. Aging
<volume>32</volume>, <fpage>2103</fpage>–<lpage>2105</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.11.016</pub-id><pub-id pub-id-type="pmid">20022408</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tocilescu</surname><given-names>M. A.</given-names></name><name><surname>Zickermann</surname><given-names>V.</given-names></name><name><surname>Zwicker</surname><given-names>K.</given-names></name><name><surname>Brandt</surname><given-names>U.</given-names></name></person-group> (<year>2010</year>). <article-title>Quinone binding and reduction by respiratory complex I</article-title>. <source/>Biochim. Biophys. Acta
<volume>1797</volume>, <fpage>1883</fpage>–<lpage>1890</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2010.05.009</pub-id><pub-id pub-id-type="pmid">20493164</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trevisson</surname><given-names>E.</given-names></name><name><surname>Dimauro</surname><given-names>S.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>Salviati</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Coenzyme Q deficiency in muscle</article-title>. <source/>Curr. Opin. Neurol.
<volume>24</volume>, <fpage>449</fpage>–<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1097/WCO.0b013e32834ab528</pub-id><pub-id pub-id-type="pmid">21844807</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turunen</surname><given-names>M.</given-names></name><name><surname>Appelkvist</surname><given-names>E. L.</given-names></name><name><surname>Sindelar</surname><given-names>P.</given-names></name><name><surname>Dallner</surname><given-names>G.</given-names></name></person-group> (<year>1999</year>). <article-title>Blood concentration of coenzyme Q(10) increases in rats when esterified forms are administered</article-title>. <source/>J. Nutr.
<volume>129</volume>, <fpage>2113</fpage>–<lpage>2118</lpage>. <pub-id pub-id-type="pmid">10573536</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turunen</surname><given-names>M.</given-names></name><name><surname>Peters</surname><given-names>J. M.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name><name><surname>Schedin</surname><given-names>S.</given-names></name><name><surname>Dallner</surname><given-names>G.</given-names></name></person-group> (<year>2000</year>). <article-title>Influence of peroxisome proliferator-activated receptor alpha on ubiquinone biosynthesis</article-title>. <source/>J. Mol. Biol.
<volume>297</volume>, <fpage>607</fpage>–<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.2000.3596</pub-id><pub-id pub-id-type="pmid">10731415</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela-Lopez</surname><given-names>A.</given-names></name><name><surname>Giampieri</surname><given-names>F.</given-names></name><name><surname>Battino</surname><given-names>M.</given-names></name><name><surname>Quiles</surname><given-names>J. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Coenzyme Q and its role in the dietary therapy against aging</article-title>. <source/>Molecules
<volume>21</volume>:<fpage>373</fpage>. <pub-id pub-id-type="doi">10.3390/molecules21030373</pub-id><pub-id pub-id-type="pmid">26999099</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>M.</given-names></name><name><surname>Mortensen</surname><given-names>S. A.</given-names></name><name><surname>Rassing</surname><given-names>M. R.</given-names></name><name><surname>Moller-Sonnergaard</surname><given-names>J.</given-names></name><name><surname>Poulsen</surname><given-names>G.</given-names></name><name><surname>Rasmussen</surname><given-names>S. N.</given-names></name></person-group> (<year>1994</year>). <article-title>Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers</article-title>. <source/>Mol. Aspects Med.
<volume>15</volume>(<issue>Suppl.</issue>), <fpage>s273</fpage>–<lpage>s280</lpage>. <pub-id pub-id-type="pmid">7752839</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcock</surname><given-names>D. M.</given-names></name><name><surname>Griffin</surname><given-names>W. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis</article-title>. <source/>J. Neuroinflammation
<volume>10</volume>:<fpage>84</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-10-84</pub-id><pub-id pub-id-type="pmid">23866266</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J. M.</given-names></name><name><surname>Florkowski</surname><given-names>C. M.</given-names></name><name><surname>Molyneux</surname><given-names>S. L.</given-names></name><name><surname>Mcewan</surname><given-names>R. G.</given-names></name><name><surname>Frampton</surname><given-names>C. M.</given-names></name><name><surname>George</surname><given-names>P. M.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia</article-title>. <source/>Am. J. Cardiol.
<volume>100</volume>, <fpage>1400</fpage>–<lpage>1403</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2007.06.030</pub-id><pub-id pub-id-type="pmid">17950797</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yubero</surname><given-names>D.</given-names></name><name><surname>Montero</surname><given-names>R.</given-names></name><name><surname>Martin</surname><given-names>M. A.</given-names></name><name><surname>Montoya</surname><given-names>J.</given-names></name><name><surname>Ribes</surname><given-names>A.</given-names></name><name><surname>Grazina</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Secondary coenzyme Q10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders</article-title>. <source/>Mitochondrion
<volume>30</volume>, <fpage>51</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.mito.2016.06.007</pub-id><pub-id pub-id-type="pmid">27374853</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yubero</surname><given-names>D.</given-names></name><name><surname>O'callaghan</surname><given-names>M.</given-names></name><name><surname>Montero</surname><given-names>R.</given-names></name><name><surname>Ormazabal</surname><given-names>A.</given-names></name><name><surname>Armstrong</surname><given-names>J.</given-names></name><name><surname>Espinos</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Association between coenzyme Q10 and glucose transporter (GLUT1) deficiency</article-title>. <source/>BMC Pediatr.
<volume>14</volume>:<fpage>284</fpage>. <pub-id pub-id-type="doi">10.1186/s12887-014-0284-5</pub-id><pub-id pub-id-type="pmid">25381171</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>M. E.</given-names></name><name><surname>El-Bassyouni</surname><given-names>H. T.</given-names></name><name><surname>Tosson</surname><given-names>A. M.</given-names></name><name><surname>Youness</surname><given-names>E.</given-names></name><name><surname>Hussein</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Coenzyme Q10 and pro-inflammatory markers in children with Down syndrome: clinical and biochemical aspects</article-title>. <source/>J. Pediatr).
<volume>93</volume>, <fpage>100</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.jped.2016.04.012</pub-id><pub-id pub-id-type="pmid">27770619</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>J.</given-names></name><name><surname>Bo</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Effects of coenzyme Q10 on markers of inflammation: a systematic review and meta-analysis</article-title>. <source/>PLoS ONE
<volume>12</volume>:<fpage>e0170172</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0170172</pub-id><pub-id pub-id-type="pmid">28125601</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>